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Chronic  lymphocytic  leukemia  (CLL)  is  a  cancer  affecting  B-lymphocytes.  Predominately
diagnosed in the elderly, treatment decisions can be complicated by factors including patient
frailty, and widely varying disease prognoses. Existing markers like IGHV mutational status are
capable of stratifying patients into two primary risk categories.  Median survival  for stage A
patients with mutated IGHV was shown to be 3 times longer. While useful, existing markers
were developed before the recent increased use of targeted therapies. These often target proteins
involved in phosphotyrosine (pY) signaling in the B-cell receptor (BCR) pathway. Using SH2
profiling,  we  studied  this  signaling  state  to  develop  novel  markers  and  identify  signaling
differences  between  subtypes  of  the  disease.  SH2  profiling  utilizes  endogenous  signaling
machinery, the SH2 domain, to quantify phosphotyrosine residues. SH2 domains bind distinct
but overlapping sets of tyrosine phosphorylated peptides allowing better coverage with fewer
probes. Using SH2 binding data from CLL patient blood samples, we have created a predictive
model for the future probability of suffering an adverse event. To understand the mechanism
behind this model, we used SH2-phosphosite binding data sets and our own novel analytical
application to generate lists of associated sites and proteins of interest. Last, we adapted existing
BCR signaling models to study the effects of perturbing several of these proteins. This approach
offers a new direction for the top-down study of CLL signaling and potentially other cancers as
well. Using this approach we hope to predict the behavior of tumors as well as understand the
mechanistic basis underlying predictors. 
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The overall goal of this thesis is to apply computational methods to improve the processing and 
analysis of biochemical data associated with the study of B-cell signaling in Chronic Lymphocytic 
Leukemia (CLL). 
In chapter 2, we will discuss the application of statistical and machine learning models to 
predict progression free survival (PFS) and to identify the biochemical probes most associated with the 
predictive ability of these models.
In chapter 3, we will continue on the exploration of the biological underpinnings for these 
predictions by investigating protein-protein interactions associated with these biochemical probes. As 
part of this, we will demonstrate a graphical tool for the exploration and analysis of binding data 
characterized by large numbers of protein-protein interactions. 
In chapter 4, we will describe the construction of two B-cell receptor (BCR) signaling models 
for the analysis of important pathways associated with the statistical model and the identified protein-
protein interactions. 
1.2 Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is a slow growing cancer of the blood where B lymphocytes 
accumulate in the blood, bone marrow and other lymphoid tissues (Kipps et al., 2017). CLL accounts 
for about one quarter of the new cases of leukemia and is expected to result in approximately 3930 
deaths in 2019 in the United States (American Cancer Society, 2019). With a median age of diagnosis 
of 72, CLL is a disease primarily affecting the elderly (Siegel et al., 2012). The time a patient can go 
before requiring treatment can vary from months after diagnosis to years or even the rest of their lives 
(Kipps et al., 2017).
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As suggested by the name, CLL is a type of leukemia, which is a type of cancer affecting the 
white blood cells, the blood cells that are part of the immune system. CLL affects a specific type of 
white blood cells called B-cells or B lymphocytes, cells often found in the lymphatic system. B-cells 
are part of the adaptive immune system and are more commonly known for their role in producing 
antibodies to fight off infection. To reach their mature state where they carry out this role, these B-cells 
must undergo several steps or changes. The end goal of these changes is to improve the chances that 
immunoglobulins produced by a B-cell will be able to recognize an antigen from a foreign pathogen 
without attacking parts of its natural environment (i.e. not self-reactive). These changes occur in the 
various lymphatic tissues, bone marrow, lymph nodes and spleen. They consist of a variety of genetic 
changes (to introduce heterogeneity in the population of immunoglobulins creating a population of B-
cells recognizing many different types of molecules) and selection steps (to remove autoreactive or 
poor performing B-cells). The first stages in B-cell maturation occur in the bone marrow, where 
immunoglobulin diversity is increased through a process called VDJ rearrangment (Brack et al., 1978). 
Upon leaving the bone marrow, the mature B-cell will move on to the spleen or lymph nodes where it 
may be exposed to pieces of a foreign invader, referred to as antigen. In the lymph nodes or spleen, B-
cells that interact with an antigen undergo further changes. In order to create B-cells with B-cell 
receptors (BCR) with the highest affinity, these cells undergo clonal expansion and somatic 
hypermutation before being positively selected for the strongest interactions. The cells whose BCRs 
have the strongest interactions then move on to become plasma cells, which secrete antibodies, or 
Memory B-cells, which remain after the infection is gone to protect from infection from the same 
pathogen (ten Hacken et al., 2019). 
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Many stages in this process depend on the interaction with the BCR and some target molecule, 
either self-derived during negative selection for auto reactivity or externally derived during positive 
selection. As a result of this interaction, the BCR signaling pathway is activated, mediating the 
response of the cell (Figure 1). The initial step in this pathway involves the BCR complex, which 
consists of immunoglobulin immobilized in the membrane (IgM) that is bound with CD79a and CD79b
(Igα & Igβ). This complex allows an event outside the cell, antigen binding to IgM, to be translated into
an event inside the cell, phosphorylation of CD79a and Cd79b. This phosphorylation of these proteins 
is mediated by Lyn (Yamamoto et al., 1993) and SYK (Rolli et al., 2002), two tyrosine kinases. The 
phosphorylation of these proteins promotes the binding and recruitment of other proteins including 
kinases (SYK, BTK and Lyn) and adapter protein BLNK through their Src Homology 2 (SH2) 
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Figure 1: Overview of BCR signaling. 




























domains. The adapter protein BLNK has been shown to mediate SYK-dependent BTK activation (Baba
et al., 2001). BTK plays an important roll in several pathways controlling B-cell migration, adhesion, 
self-tolerance, immune activation and cytokine secretion (Xia et al., 2015). Activation of BTK causes 
the phosphorylation of PLCγ2, leading to the conversion of phosphatidylinositol-4,5-biphosphate 
(PI(4,5)P2) into diacylglycerol (DAG) and inisotol triphosphate (IP3). Production of IP3 leads to 
elevated Ca2+ levels and later activation of the transcription factors NF-κB and N-FAT. Increased levels 
of DAG lead to downstream activation of the MAPK family pathways (Dal Porto et al., 2004).
As shown in Figure 2, CLL can be split into different subtypes which correspond with different 















Figure 2: Subtypes of CLL related to different stages of B-cell maturation . 
After undergoing maturation in the bone marrow, B-cells can aggregate to form follicles in the 
lymphatic system. In these follicles, B-cells normally undergo somatic hypermutation, and it is the 
presence or absence of this process which is tied to the difference in mutational status of IGHV in CLL.
to the presence or absence of mutations associated in the immunoglobulin heavy-chain variable region, 
a result of the somatic hypermutation step of B-cell maturation (Kipps et al., 2017; Hamblin et al., 
1999; ten Hacken et al., 2019). These subtypes also tend to classify the patients into high and low risk 
groups with the U-CLL subgroup associated with a less mature B-cell and higher risk. U-CLL patients 
were shown to have an median survival of 95 months vs. a median survival of 293 months for M-CLL 
patients (Hamblin et al., 1999). This is one of several markers currently used to stratify patients. 
Another marker associated with higher risk is the ectopic expression of ZAP70, a signaling protein 
more often associated with T lypmphocytes (Kipps et al., 2017). Currently, there there are many factors
to take into account when planning a patient’s therapy course. In some cases these factors have been 
combined into prognostic indexes (International CLL-IPI working group, 2016; Pflug et al., 2014) or 
nomograms to improve predictions of clinical outcome (Wierda et al., 2007). Within these studies, the 
common factors tend to be age, IGHV mutation, TP53 status, and clinical stage, with some variation 
depending on the time of the study and the datasets available. 
While many factors with prognostic values exist, there is interest in understanding the 
underlying signaling of CLL and in particular the BCR signaling pathway. There are a number of 
pieces of evidence suggesting the importance of the BCR pathway in CLL and one of these is the 
connection of patient prognosis to both the mutational state of the IGHV region of the BCR and the 
ectopic expression of ZAP70 (Pede et al., 2013; ten Hacken et al., 2019). In addition to representing a 
different stage in B-cell maturity, the IGHV mutational status also represents a functional change in the 
BCR. The antigenic determinants (epitopes) of U-CLL vs M-CLL subsets have been characterized as 
having higher poly-reactivity vs. higher BCR specificity, respectively (ten Hacken et al., 2019). Often 
the unmutated state is accompanied by the ectopic expression of ZAP70, a structurally homologous 
protein to SYK,which has also been shown to enhance phosphorylation of SYK, BLNK and PLCγ 
(Chen et al., 2005; Pede et al., 2013). Thus prognostic status is correlated with changes in the 
6
specificity of the B-cell receptor as well as changes in phosphorylation levels of several BCR pathway 
proteins. Another piece of supporting evidence is the activation of BCR pathway in the lymph node 
microenvironment of CLL patients (Herishanu et al., 2011). When combined with the effectiveness of 
targeted kinase inhibitors for BTK (Byrd et al., 2013), SYK (Friedberg et al., 2010) and PI3K (Furman 
et al., 2014), the argument for the importance of the BCR in CLL is is further strengthened. While not 
all are tyrosine kinases, the target proteins of these enzymes all share a strong connection to 
phosphotyrosine signaling through their respective SH2 domains as outlined below.
1.3 Phosphotyrosine Signaling and SH2 Domains
Phosphotyrosine signaling is an important aspect of the BCR signaling pathway, with a number 
of kinase, phosphatase, and SH2 domain containing proteins. As explained by Lim et al., one can look 
at these three main players as a writer, eraser and reader, respectively. First the tyrosine kinases (Lyn, 
SYK, BTK) are responsible to writing the signal or catalyzing the phosphorylation of tyrosines in the 
target protein. The second group, the phosphatases are responsible for the removal of that signal by 
catalyzing the removal of the phosphate group. Last the Src Homology 2 (SH2) domains are modular 
protein domains known for their characteristic ability to recognize phosphotyrosines and act as the 
reader in this system (Lim and Pawson, 2010). 
Each SH2 domain has a preference for binding sites with certain sequences flanking the 
phosphotyrosine. For many SH2 domains this preference has been characterized and described using 
motifs. For example, Grb2 SH2 preferentially binds sites with an asparagine two positions after the 
tyrosine and is described by the motif YXN (Songyang et al., 1994). The X in the motif represents no 
preference for a specific amino acid. With binding preferences for both the phosphorylated tyrosines 
and the local amino acid residues, SH2 domains posses a unique level of specificity, in between a 
phospho-specific antibody and the more general phosphotyrosine antibody.
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By linking modular kinase or phosphatase domains with an SH2 domain, amplifications or 
reductions in signal can occur in response to a change in the set of available phosphosites. This is due 
to the fact that specific signaling events are typically associated with a specific localization in the cell. 
With early BCR signaling, much of this activity is at the membrane at or near the receptor itself. Thus 
for these signaling reactions, the concentrations that matter are the local concentrations at the 
membrane, not the concentration in the entire cell. One way to alter these local concentrations is 
through the interaction of SH2 domains and proteins containing phosphotyrosines. To increase the local
concentration of an SH2 containing protein, one can increase the number of binding sites 
(phosphotyrosines) for that SH2 domain. In BCR signaling, phosphorylation of CD79a and CD79b 
results in the binding and increased local concentrations of a number of different proteins. These 
changes in local concentration then result in changes to the local kinase or phosphatase activity, which 
leads to further changes in phosphorylation. These changes can lead to other signaling events and 
ultimately impact cell fate. The importance of phosphotyrosine signaling in CLL can be further 
bolstered with the success of the tyrosine kinase inhibitors BTK (Byrd et al., 2013) and SYK 
(Friedberg et al., 2010) for treating CLL.
With the importance of phosphotyrosine signaling and the role of the SH2 domain as the natural
reader of that signaling, a method has been developed to use these domains as a way to probe the 
phosphotyrosine signaling state. The technique of SH2 profiling uses recombinant versions of 
endogenous SH2 domains to assess the abundance of phosphorylated tyrosines in a sample and the 
affinity or strength of binding to these tyrosines. Depending on the amount of signal granularity 
desired, samples, which are often cell lysates, can be either directly spotted onto nitrocellulose 
membranes or first separated by molecular weight. These membranes are then probed with the SH2 
domain fused with GST. Later this can be visualized using secondary antibodies for glutathione S-
transferase (GST) conjugated with Horseradish peroxidase (HRP) or fluorescent labels (Machida et al., 
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2007). Separation by gel electrophoresis can yield a measurement of the molecular weight of the 
phosphosite containing protein, aiding in identification of a specific SH2 binding site. 
In general, SH2 profiling is a sensitive and rapid technique for the assessment of the 
phosphotyrosine signaling state of a sample (Machida et al., 2003). With a little over a hundred SH2 
domains in the human genome, is requires much smaller set of probes when compared to the use of 
phosphospecific antibodies (pTyr antibodies recognize all tyrosine phosphorylated proteins, 
phosphospecific only recognize a single phosphorylated site). In addition, this technique takes 
advantage of the endogenous nature of the SH2 domain to capture the phosphotyrosine signaling state 
in a functionally relevant way; e.g. an increase in PLCγ binding sites implies an increase in PLCγ 
activity. Thus the binding signals obtained from this method can be expected to retain their connection 
to the underlying biology. This is important because the SH2 domains can act as type of biology-driven
dimensionality reduction for input data which can be beneficial for creation of predictive models, 
particularly when the sample size is small. 
With the use of this SH2 domain binding data we seek to utilize both statistical and mechanistic 
modeling as a top-down approach for characterizing the underlying biology. Statistical and mechanistic
modeling work well together because they have contrasting sets of limitations and strengths. Statistical 
modeling relies little on prior knowledge of the underlying biology and seeks only to best represent the 
relationships in the current dataset. Thus, statistical models can be useful for making predictions in a 
clinical setting (Baker et al., 2018) . Statistical models are limited however, in their ability to elicit the 
underlying causes associated with potential markers they identify. These models may identify an 
important SH2 domain, but will offer little to no additional insight to the underlying upstream 
mechanism. Mechanistic modeling is better suited for this goal. These models are based on the process 
of testing and incorporating hypotheses for the underlying causal mechanisms (Baker et al., 2018).This 
level of detail in mechanistic modeling can allow one to ask and answer more in-depth questions about 
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the associated biology. In addition, mechanistic models are more powerful for predicting the effects of 
a new treatments (Baker et al., 2018). This is due to the fact that statistical models cannot pull from the 
base of knowledge of signaling pathways and related molecules. With complementing sets of 
advantages, the combination of statistical and mechanistic modeling can be a powerful set of tools for 
the investigation and treatment of diseases.
1.4 Survival Analysis & Predictive Models
One of the goals of our work is to identify an SH2-based marker to identify different risks of 
disease progression. Specifically we were interested in using SH2 domain binding data to predict the 
amount of time before a patient would require therapy. When following patients in a clinical study, 
where the output is the time to a specific event (i.e. death or required treatment), one challenge with the
characterization of said output lies with how one deals with patients that withdraw from the study 
without experiencing such an event. A simple approach might be to exclude those patients from the 
study entirely, this however would waste valuable information and could skew the results. To deal with 
this problem of incomplete data, Kaplan and Meier outlined a non-parametric method that can be used 
to estimate survival probability from observed survival time (Kaplan E. L. and Meier Poul, 1958). This 
requires the knowledge of both the time observed and the status at the end of this time. This status 
refers to whether the patient had the event of interest at that time. If they did not experience the event 
of interest then the sample is said to be censored. A dataset containing this time to event and status 
information is referred to as right censored data or also survival data. When a sample is censored, the 
time t only indicates the time in which one knows that the subject did not have an event. This time 
could refer to non disease related reasons; study ending, leaving the study for personal reasons or 
suffering an unrelated illness. In these cases it is said that the survival time for that subject cannot be 
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accurately determined. This data can then be used to create an estimate of the survival function or the 
function that defines the probability of surviving to a specific time. 
To conduct this analysis, samples are arranged in a table in ascending order of the observed 
time. Then working down the table for each time point, one can calculate the surviving proportion at 
that time point or the proportion of participants that do not experience an event at that time point. This 
proportion represents the probability of survival past this point given the fact that they had survived 
past all of the previous points. By multiplying this value with all of the proportions for all of the 
previous points, one can calculate the cumulative probability of surviving (Goel et al., 2010). This 
cumulative probability can be visualized in a Kaplan-Meier or survival curve with the drops 
representing times where events were registered and the height of the drops reflecting the change in the
cumulative probability (for an example, see Figure 3) (Rich et al., 2010; Bewick et al., 2004). The 
censored points (“+” symbols) do not result in drops in the curve but have an effect on the cumulative 
survival measurement by reducing the number of available observations for the surviving proportion 
calculation. In figure 3, the dataset initially contains five samples. Moving along the time line one can 
see a sample is censored at ten months. This reduces the available observations from 5 to 4 but does not
cause a drop in survival probability. For each of the the first two events there is a reduction in the 
probability by 25% due to the fact that each represented one fourth of the population remaining in the 
study. After an additional sample is censored at 30 months, the final event results in a drop to zero due 
to the fact that it represents the entire population remaining. Visually these curves can be used to 
compare groups of observations, but there also exists a statistical hypothesis test which can be used to 
test if there is a difference between the two samples. The log-rank test compares the differences in 
expected and observed events for each group under the assumption of proportional hazards which will 
be discussed below.
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While the Kaplan-Meier curve is based on the estimation of the survival function (the 
probability of surviving to time t), there exists a second metric of interest, known as the hazard which is
the conditional probability of observing the event (requiring treatment, death) at a time, t. This metric is
important because it is at the core of several techniques, one of which is the log-rank test. As briefly 
mentioned earlier, the log-rank test relies on the assumption of proportional hazards. Simplified, 
proportional hazards assumes that the difference between the logarithms of the hazards between two 
groups does not change with time (Bewick et al., 2004). Failure of this assumption can be seen visually
when looking at a plot of the cumulative hazard in log scale vs the survival time in log scale. If the 
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Figure 3: Example plot of Kaplan-Meier estimate for survival function. 
Events are represented as drops in the survival probability and censored subjects are marked with a 
“+”.
lines for the two groups are roughly parallel, then the assumption holds (Bewick et al., 2004). This 
assumption is also important for the Cox regression, a popular model which will be introduced below.
Cox proportional hazards regression (Cox, 1972) is another method to test the difference 
between survival times, which also yields a relationship between explanatory variables and the hazard 
at time t. The formula ln(
h(t)
h0(t)
)=b1 x1+...+bp x p shows the basic premise of the model. In this form 
the x refers to the values of the explanatory or independent variables and b represents the coefficients 
that the regression is searching for. In this case, the dependent variable is the log of the ratio of the 
hazard at time t divided by the baseline hazard at time t. If the proportional hazards assumption holds 
then this baseline hazard would be constant and can be treated similar to the y intercept in the formula 
for a line. Once fit, the values for b represent the effects of the parameters or coefficients on the log of 
the hazard. Using this method a negative b value suggests a variable is protective as it suggests a lower 
hazard for increasing values for that variable. While useful, Cox regression suffers from a few 
challenges, one is as mentioned the proportional hazards assumption. In addition, Cox regression 
requires the use of functions to deal with nonlinearity potentially complicating the analysis. Last, 
methods for identifying statistically significant variables have been criticized for being unreliable, 
creating bias and being difficult to interpret (Hsich et al., 2011).
As an alternative, random survival forests have been used for identifying risk factors in survival
of patients (Hsich et al., 2011). Random survival forests are an adaptation of random forests for the 
analysis of right censored survival data (Ishwaran et al., 2008). Random forest is an ensemble approach
which utilizes the learning mechanism of decision trees. Decision trees are a popular machine learning 
method due to their speed, interpretability, and resistance to predictor outliers and irrelevant predictor 
variables (Hastie et al., 2009). They function by separating the data into smaller and smaller groups 
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(recursively) using rules based on the input variables or predictors. At each step or split the algorithm 
chooses the test that will best split the current group of data (Geurts et al., 2009). This process 
continues, creating more and more splits until some split stopping criteria is reached (Geurts et al., 
2009).The name decision tree can be seen when the final predictor is visualized, as it takes a tree-like 
structure which resembles the decision process a clinician might follow (Hastie et al., 2009). 
Despite the advantages, decision trees suffer from inaccuracy, leading to the use of ensemble 
methods that take advantage of randomization or boosting (Geurts et al., 2009). Instead of generating 
one decision tree, these methods generate multiple trees while differing largely in the way these trees 
are generated. In boosting methods, models or trees are generated sequentially with each new tree 
addressing the deficiencies of the former (Geurts et al., 2009). The final prediction is then a weighted 
average of the results of these trees (Geurts et al., 2009). In contrast, Breiman’s implementation of 
Random Forests creates each tree separately by randomly selecting a set of samples for each tree and a 
set of features for each split. Each tree then votes to form the final predictor.
For each tree in a random forest, randomness is added in two ways. First, for each split in a tree,
available features are randomly sampled and only those can be used for creating the split (Breiman, 
2001). Second, each tree is trained using a randomly selected subset of the data with approximately one
third of the samples left out (Breiman, 2001). Since each sample will be left out from the training of 
some trees, it is referred to as “out of bag (OOB)” for these trees, and it can be used to calculate an 
estimate of error. For each sample, the out of bag predictor is constructed using only the trees where 
that sample was out of bag and thus was not used for training. Using the same voting procedure, these 
trees can make the prediction which can be used to calculate the error estimate. This allows for an error
estimate to be calculated as the forest is grown (Breiman, 2001).
Random survival forests (RSF) expanded on the Random Forest method by adapting it for use 
with survival data. Similar to random forest, RSFs progressively split the dataset using the most 
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optimum variable and specifically try to maximize the survival difference between daughter nodes 
(Ishwaran et al., 2008). Similar to RF, criteria can be set to define when to stop splitting, but RSF also 
has the constraint that each node must have more than 0 unique deaths (Ishwaran et al., 2008). To make
a prediction, a set of feature values is passed down a decision tree and the cumulative hazard function 
(CHF) of the samples in the terminal node is calculated. This CHF can be averaged across all of the 
trees in the forest, resulting in the ensemble CHF (Ishwaran et al., 2008). Previously, we discussed the 
hazard function for a survival dataset as the probability of a subject experiencing an event after 
surviving to time t. The cumulative hazard function is the integral of the hazard function when 
evaluated from time 0 to time t (Miller, 1998). The random survival forests method also has a internal 
measure for error rate using OOB samples by taking advantage of Harrel’s concordance index. This 
index can be interpreted as the probability of misclassification and more specifically the probability 
that, from a pair of cases, the case that fails first had the worse predicted outcome (Ishwaran et al., 
2008). Thus there are a number of statistical methods one can use to analyze the association of a 
particular marker or set of markers to with clinical outcomes.
1.5 Sequence Logo Visualization
When studying protein attributes that may affect binding, one key attribute is the amino-acid 
sequence of the protein. In studies of modular protein-protein interactions it is not uncommon to try to 
describe the group of proteins that bind by some representative sequence (Miller et al., 2008; Tinti et 
al., 2013). While this may seem like a straightforward concept, the method for conveying this 
information is not trivial.
One of the simplest displays of this sequence information is the consensus sequence. A 
consensus sequence shows the most frequent base or residue in each position. While simple to 
construct, consensus sequences only convey a small amount of information. While it may show the 
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most prominent amino acid, there is no information about how prominent it is in relation to the other 
potential amino acids. In some cases, a particular residue can be the most prominent while representing 
less that 50% of the samples. If one was using the consensus sequence to identify new potential sites of 
interest, they would be ignoring half of the potential sites just based on the lack of information for that 
one position. When compounded over multiple locations this tool can quickly lose its ability to identify
new sites. One example is that of the Pribnow Box, which has a TATAAT consensus sequence, where 
the highest rate for any position is less than 90% and several of the positions are less than 60% (Sorkin 
and Westermark, 1991). Given the original database of 291 promoter sequences that this consensus 
sequence is attempting to represent, the exact consensus sequence is only present 14 times in the 
database (Schneider, 2002). While the search can be less restricted, a researcher using the consensus 
sequence alone will not know in which positions a mismatch is more important (Schneider, 2002). 
In order to retain some of the information lost with a consensus sequence, Schneider et al 
developed a visualization method referred to as the sequence logo (Schneider and Stephens, 1990).  
This contains not only the most prominent residues as in the consensus sequence, but includes the 
relative frequency of the other residues as well. In addition, the figure generated with this method 
contains the amount of information contained at every position, measured in bits (Schneider and 
Stephens, 1990). The information contained, in bits, can be used as a measurement for the conservation
of an amino acid or acids at a position. This measurement can be explained more clearly when 
discussing DNA sequences for potential transcription factor binding sites. For each position the base 
can be described with two yes or no questions. Is it an A or T? Is it an A or C? If yes to both it is an A; 
no to both, it is a G; and yes to only one will indicate if it is an T or a C. Thus knowledge that an A 
always exists in a position of a genetic sequence indicates the position contains 2 bits of information as 
it can be represented by two yes answers. If the base can be narrowed down to two candidates A or T, 
then it would contain only one bit of information as it could be answered with the first yes or no 
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question (Schneider, 2002). For the description of a binding site in a nucleic acid or protein, positions 
which are important for the specificity of binding should have less variation between sequences and 
thus would contain more information. A residue where tyrosine is present in all of the sequences would 
contain approximately 4.32 bits of information log2(20)≈4.32 . When compared to the consensus 
sequence, the information content allows a measurement of the distribution of amino acids in a 
position, which would be completely lost in the consensus sequence. In the context of the sequence 
logo, which displays the frequencies of the amino acids, the information content (bits) provides a 
statistic of the distribution of these amino acids, similar to how a standard deviation can describe the 
distribution of a set of data points. The combination of the display of the information content and the 
relative frequencies in the sequence logo allows the researcher to have both quick parametric and more 
detailed information conveyed. 
To make sequence logos accessible for researchers, they have been implemented in several web 
applications and software packages. WebLogo (Crooks et al., 2004) and Seq2Logo (Thomsen and 
Nielsen, 2012) both can take a list of amino acid sequences and return a sequence logo without any 
knowledge of programming by the user, while RwebLogo (Wagih, 2014) and ggseqlogo (Wagih, 
2017) can generate sequence logos using R (R Core Team, 2019), a language and environment for 
statistical computing. In efforts to improve on the standard implementations of sequence logos several 
tools have been created. In addition to the enrichment of specific amino acids, depletion can be 
visualized using several tools including Seq2Logo, KpLogo, pLogo and EDLogo (O’Shea et al., 2013; 
Dey et al., 2018; Thomsen and Nielsen, 2012; Wu and Bartel, 2017). While these implementations of 
sequence logos offer a more complete picture of the sequence preferences of a binding site, they are all 
static representations and any adjustments to the input data must be conducted outside the application 
(Figure 4). Due to the somewhat arbitrary nature of defining binding cutoffs or thresholds, we found it 
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helpful to vary this threshold in order to gain a better understanding of the binding site preference over 
the range of affinities. With these current tools, this would require modification and multiple runs of the
data processing script. In order to explore the data, it may be necessary to run the script many times. 
While feasible, it can become cumbersome and tedious, while being limited to those with programming
experience. Thus, there is a need for a more interactive way to generate sequence logos and explore this
type of data. 
1.6 Computational Modeling of BCR Pathway
While a statistical model can be useful for the connection of SH2 binding inputs to time-to-



















Figure 4: Binding data processing flow for generating sequence logos using WebLogo
Binding data is processed to result in a set of amino acid sequences that have been defined
as binding to the site of interest. Depending on the threshold for this definition of binding, 
the sequence logo can vary. To explore the effects of varying this threshold, currently one 
must generate individual lists of sequences for each threshold 
may be responsible for this relationship. For this type of understanding a mechanistic or signaling 
model may be more applicable. Mechanistic models can be used to test hypotheses, generate new 
insights, conduct sensitivity analysis, suggest new experiments or investigate causality (Brodland, 
2015). With a mechanistic model, existing knowledge of the underlying biology is incorporated, 
allowing changes to be explored on a pathway or protein level. Once established, a model like this can 
be used to explore the effect of molecular level perturbations, allowing for the screening of potential 
drug targets. In particular, one could test the effects of perturbing likely binding sites for SH2 domains 
that serve as strong markers. Thus we sought out to establish our own mechanistic model of BCR 
signaling in CLL.
Currently several computational models for BCR signaling exist. Some like that of Barua et al. 
were focused on studying early events in BCR signaling (Barua et al., 2012). A model from McGee et 
al. (McGee et al., 2015) encompasses a larger part of the pathway, as they sought to study the effects of
small changes in early kinase activity through manipulation of SYK activity both experimentally and 
computationally. This model encompassed aspects of BCR signaling from the antigen binding event at 
the membrane to the activation of transcription factors like NF-κB (McGee et al., 2015). More recently,
other models have tried to incorporate BCR signaling in the context of B-cell related disease states. The
model by Du et al. not only encompassed equal to or greater levels of detail of BCR signaling as the 
McGee model, but combined this with a tumor growth model built for better drug screening (Du et al., 
2017). 
These models, all exist within a single compartment, which is to say that there is no spatial 
component explicitly defined in the model. One aspect of cell signaling that should not be ignored is 
the increase of local concentrations through binding interactions of proteins already in a particular 
cellular location. Proteins at a membrane that have a sudden increase in phosphorylation create 
additional binding sites for proteins with SH2 domains. This increase in binding sites can result in a 
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translocation of these SH2 domain containing proteins to the membrane. While this translocation is not 
modeled explicitly in a compartmental model, models like that in Du et al. can use binding reactions as 
requirements for later protein activation as a way of implicitly modeling this spatial aspect.
While all of the models previously mentioned are compartmental in nature, they differ slightly 
in the approach and tools used to construct them. Both the Du and McGee models specify the ordinary 
differential equations directly, while the Barua model employs the use of the BioNetGen language 
(BNGL) a language for the specification of rule-based models (Faeder et al., 2009). Rule-based models
allow for the specification of a model without explicitly defining each individual reaction or species. 
Molecules are represented as structured objects with rules allowing the modification of attributes of 
these objects (Faeder et al., 2009). Rules modifying an attribute of an object can be defined, either 
ignoring or depending on other attributes of the same object. The ability to leave an attribute as 
unspecified allows the rule to define a number of reactions and species associated with the various 
configurations of the unspecified attributes. In this way, rule-based modeling allows for the 
construction of models that would otherwise have prohibitive numbers of reactions or species due to 
combinatorial complexity. In the Barua model, RBM is used to construct a model implying a total of 
24388 reactions and 1122 species (Barua et al., 2012).
Currently many models are constructed and simulated using MATLAB, including the Du and 
McGee models listed above. MATLAB is a general purpose program for mathematical modeling 
widely used in the physical and engineering sciences (Ullah et al., 2006). While the Barua model was 
constructed using the BNGL language, the output from the network generation was run and simulated 
in MATLAB. MATLAB allows for the definition of a model through the development of the equations 
themselves or through the use of toolboxes available for modeling, simulating and analyzing 
biochemical networks (Du et al., 2017; McGee et al., 2015; Gilbert et al., 2006). While MATLAB is a 
general tool applied to the specific application of biochemical modeling, other tools such as COPASI 
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(Hoops et al., 2006) and VCell (Loew and Schaff, 2001; Resasco et al.) were designed specifically for 
biochemical modeling and offer a more graphical approach to the creation of biochemical models 
(Gilbert et al., 2006). In addition both tools are capable of importing and exporting to systems biology 
markup language (SBML) (Hucka et al., 2003) allowing for better standardization of models. VCell 
also contains a graphical framework for building and simulating rule-based models (Blinov et al., 
2017). Amongst other notable features, COPASI allows the modeler to conduct sensitivity analysis 
(Sahle et al., 2008). In addition these tools automate the enforcement of mass conservation, a challenge
whose complexity is often underestimated, leading to potential errors in models where the differential 
equations are explicitly defined. 
With the unique type of data created with the use of SH2 profiling, it is beneficial to employ 
several computational methods to fully utilize these data. When combined with clinical PFS data, 
statistical models are useful for the identification of novel, SH2 domain based, clinical markers for 
patient outcomes. Once a candidate SH2 marker is identified, however, one still needs to identify the 
individual sites that the SH2 domain is binding to in order to find biological changes associated with 
the disease. Peptide binding assays can be used to screen for the strongest binders to an SH2 domain as 
high probability targets for further investigation. This investigation can be done in silico through the 
use of a mechanistic CLL model to further explore potential causes for the potential CLL disease 
heterogeneities identified by the marker. In addition, this mechanistic model can be used to identify the 
best targets for altering the outcome of the model and creating new therapeutics. By utilizing this work-
flow, one can start with a small set of SH2 binding data and identify clinically relevant markers while 
progressively working towards a more detailed understanding of the underlying biology.
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To improve on the current success of existing prognostic indicators for CLL like IGHV 
mutational status, our lab is interested in the development of new prognostic indicators that may be 
more reflective of the internal cellular signaling. SH2 profiling offers the opportunity to elicit patterns 
within the phosphotyrosine signaling machinery itself and potentially expose important mechanistic 
insights in addition to added prognostic value. In order to develop these new biomarkers using SH2 
profiling, we set out to create several predictive models that would use the SH2 profiling data as their 
input.
2.2 Methods
2.2.1 Description of Data Set
The dataset consists of 35 subjects and from these subjects, two types of data were collected. 
SH2 profiling data was obtained from blood samples obtained from the initial visits of these subjects. 
Briefly, this involved isolation of the white blood cells before lysing and spotting on a nitrocellulose 
membrane. The membranes were then probed using the five SH2 domains (BLNK, Lyn, BTK, PI3K, 
and PLCγ) and were quantified. These five domains were selected for their high signal to noise ratio 
from a panel of SH2 domains associated with the BCR signalosome. For more information on the 
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Figure 5: Progression Free Survival Definition. 
Progression free survival is defined as the time from the collection of the initial sample to the most 
recent timepoint collected. The status at the final timepoint indicates whether endpoint is related to the 
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process of SH2 profiling please refer to (Machida et al., 2010). In addition to this biochemical data, 
subjects were followed over the course of their study to assess the amount of time before they required 
treatment or died. This time is referred to as the progression free survival (PFS). This can be seen in 
figure 5. Within the data set, roughly one third of subjects have required treatment or suffered a 
disease-related event (Figure 6 Section A). Of these events more than half occur before 50 months as 
can be seen in Figure 6 Section B. 
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Figure 6: Distribution of Subjects by Status and Time. 
(A) Number of subjects who experienced an event or were considered censored within the timeframe of 
the study. (B) Distribution of time elapsed for subjects split by status
Using the Kaplan-Meier estimator and this data one can visualize the estimated survival probability 
over time as shown in figure 7. 
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Figure 7: Kaplan Meier Estimate of Survival Function of Dataset. 
In the curve, “+” marks represent censored subjects, while the events are denoted as drops in the 
survival probability. This is also referred to as the null model used for comparison with other models. 
The shaded region represents the 95% confidence interval for the survival probability estimate. 
Figure 8 shows the overall distribution of the SH2 domain binding data. This combination of PFS and 
SH2 profiling data was then used for the following analysis.
2.2.2 Analysis in R
For all data analysis and predictive modeling, work was done using the R statistical programming 
environment (R Core Team, 2019). Data manipulations were conducted with the use of the tidyverse 
(Wickham, 2017) suite of data manipulation packages and the package readxl (Wickham and Bryan, 
2019). Cox regression analysis was conducted with the use of packages survival (Therneau and 
Grambsch, 2000), survminer (Kassambara et al., 2019) and powerSurvEpi (Qiu et al., 2018). Random 
forest analysis was conducted using randomForestSRC (Ishwaran et al., 2008). Predictive models were 
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Figure 8: Distribution of SH2 Domain Binding Data.
assessed with ten-fold cross validation using the Prediction Error Curve (PEC) package (Mogensen et 
al., 2012).
2.2.3 Random Forest Generation
Random survival forests were trained using the RandomForestSRC package in R and assessed using 
the prediction error curve (PEC) package. The parameters for terminal node size (nodesize) and the 
number of variables randomly selected as candidates at each split (mtry) were selected using grid 
search and optimized to reduce out of bag (OOB) error. These were set at 1 and 1, respectively. The 
number of trees was selected to be large enough so that random fluctuations no longer had an effect on 
variable importance. The choice of 2000 trees still resulted in models that trained in seconds or less. 
2.2.4 Model Evaluation
Models were evaluated using ten-fold cross validation and the prediction error and integrated Brier 
scores (IBS) [defined below] were compared. For cross validation, data is split into ten equal parts, 
nine of which are used to train the model and the remaining part is used to test the prediction error. This
is repeated for each of the ten parts and the prediction error is averaged over the ten runs. Prediction 
error is calculated as the Brier score and curves are generated by following this over time (Mogensen et







2  is the mean squared difference between the predicted 
probability of the event occurring f t and the status of whether the event has already occurred for that 
sample ot , for a given time t (Roulston, 2007). The probability can be any number between 0 and 
1 and the status should be exactly 0 or 1 as it represents the status for a specific sample at a specific 
time. The Brier score will be calculated and averaged for all of the samples in the data subset not used 
for the training of the model. This value can then be plotted vs time displaying the performance of each
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model at all given time points (figure 9). As a baseline, models are compared against a reference model.
This reference model is the prediction error if one were to use the Kaplan-Meier estimator and ignore 
the SH2 domain data. If one wants to compare models taking into account a range of time points, the 
Brier score can be integrated over those time points resulting in the integrated Brier score (IBS). 
Models were selected based on the lowest IBS at 100 months. 
2.3 Cox Regression Results
The data was analyzed in several ways using statistical tools. When used to create a Cox proportional 
hazards model, BLNK was the only SH2 domain to have a significant regression coefficient. This 
suggests it could be a good prognostic factor with a log hazard ratio (regression coefficient) of -6.5 and 
a p value of 0.019 (Table 1). For further background on the relationship of the hazard ratio and the 
coefficient, please refer to section 1.4. The p-value represents the probability that the coefficient for 
BLNK is actually zero and thus a lower p-value suggests that there may be a relationship there. While 
significant for the one test, the testing of multiple hypotheses (5 SH2 domains) increases the type I 
error or chance of false positive to ~0.226 from 0.05. To compensate, a threshold of 0.01 for accepting 
or rejecting the null hypothesis may be more appropriate. This does not indicate that the relationship is 
not there, just that one may require more samples to confidently reject the null hypothesis that the 
coefficient for BLNK is 0.
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Table 1 : Coefficients and other outcomes from multiple univariate Cox proportional hazards models
Regression Coefficient Hazard ratio P Value
BLNK -6.52 0.001 0.019
BTK -2.98 0.051 0.281
Lyn -0.06 0.941 0.978
PI3K -0.29 0.749 0.946
PLCγ2 -2.18 0.113 0.495
Table 2 Integrated Brier score at various time points for various Cox models
Time (months) 20 40 60 80 100
Reference 0.089 0.142 0.169 0.182 0.198
Cox_all 0.119 0.152 0.172 0.185 0.214
Cox_BLNK 0.093 0.144 0.165 0.179 0.197
Cox_Lyn 0.090 0.146 0.176 0.190 0.207
Cox_BLNK_Lyn 0.091 0.137 0.154 0.161 0.181
Cox_BLNK_BTK 0.094 0.145 0.167 0.182 0.200
Cox_BLNK_PI3K 0.099 0.156 0.184 0.202 0.232
Cox_BLNK_PLCγ 0.097 0.152 0.179 0.189 0.206
Evaluation of several model combinations centering on BLNK, showed that the optimum model
utilizes both BLNK and Lyn resulting in the lowest Integrated Brier score of 0.181 (Table 2). The 
prediction error over time can be seen in Figure 9. From Figure 9 one can see that several of the 
models, particularly those containing BLNK, performed better than the reference.  Interestingly the 
Cox model with all 5 SH2 domains (light blue) does not perform the best and in some cases performs 
the worst. Thus it seems that the model may be over fitting when using all 5 SH2 domains. Over fitting 
is often associated with too much model complexity and regression techniques like CoxPH tend to 
suffer from over fitting as more and more variables are included. One way of reducing that complexity 
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is through feature selection and the performance of the BLNK-Lyn model shows the benefits of such 
reductions. Thus, not only is the BLNK-Lyn model is the best performing of the CoxPH models, it also 
outperforms the baseline model suggesting its potential for predicting clinical outcomes.
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Figure 9: Comparison of Potential CoxPH Models. 
Measurement of the average Prediction error during 10 fold cross validation. Prediction error is 
calculated as the mean squared difference between the predicted probability of an event at time t and 
the status of a subject at time t. Predicted probability was compared for several BLNK SH2 based Cox 
models. Cox_all represents a model using all five of the SH2 domains. Lower predicted errors suggest 
a more accurate model. Reference model is Kaplan-Meier estimate of survival probability shown in 
Figure 7. 
While useful, one of the concerns with the CoxPH model is its ability to handle nonlinearities. 
By trying to fit the data to the formula ln(
h(t)
h0(t)




is related to the predictor x in a linear fashion. If the relationship between a 
predictor and the log hazard ratio is nonlinear, the model will not perform as well. With the expectation
that the underlying biological mechanisms could be related to the BCR signaling network, the 
possibility of nonlinearity should not be ignored. Signaling networks often contain feedback and or 
feed forward loops which can create nonlinear relationships. With this in mind, we also created a 
random forest model for the prediction of patient outcomes. Random forest can be a good choice when 
there is the possibility of nonlinearities in the data. 
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2.4 Random Forest Results
In agreement with the Cox analysis, measures of variable importance suggested BLNK as the 
most important marker (Figure 10) and as a result the following random forest models centered on 
BLNK. From Figure 11 it is difficult to identify the best performing version of the random forest and 
thus it is necessary to look at the integrated Brier score. Looking at the integrated Brier scores in table 3
one can see that rf_BLNK_Lyn still performs the best, but now the rf_all model is performing equally 
as well. This may be due to the fact that random forest tends to be more resistant to over fitting than 
Cox regression. 
32
Figure 10: Variable importance of SH2 domains in random forest model
Table 3 :Integrated Brier Scores For Various Random Forest Models
Time (months) 20 40 60 80 100
Reference 0.088 0.139 0.166 0.180 0.195
rf_all 0.071 0.109 0.123 0.134 0.147
rf_BLNK 0.105 0.144 0.150 0.153 0.168
rf_Lyn 0.103 0.133 0.147 0.153 0.171
rf_BLNK_Lyn 0.090 0.116 0.123 0.129 0.147
rf_BLNK_BTK 0.089 0.141 0.157 0.171 0.187
rf_BLNK_PI3K 0.074 0.121 0.133 0.142 0.155
rf_BLNK_PLCγ 0.083 0.117 0.132 0.141 0.155
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Figure 11: Comparison of Potential Random Forest Models.
Measurement of the average prediction error during 10 fold cross validation. Prediction error is 
calculated as the mean squared difference between the predicted probability of an event at time t and 
the status of a subject at time t. Predicted probability was compared for several BLNK SH2 based 
random forest models. RF_all represents a model using all five of the SH2 domains. Lower predicted 
errors suggest a more accurate model. Reference model is Kaplan-Meier estimate of survival 
probability shown in Figure 7. 
When compared with the Cox models (Figure 12), the Random Forest models tended to 
outperform. This can be confirmed when looking at the Integrated Brier Scores in Table 4. Of note, the 
IBS scores between the different comparisons vary slightly from table to table. This is due to the 
random nature of the cross validation and the generation of the forests. While it is possible to set the 
seed to control this, repeated measures allowed additional insight in the case of RF_BLNK_Lyn and 
RF_all. This resulted in RF_BLNK_Lyn being better in some but not all of the instances. It did appear 
that when RF_all is better it is only by a very small margin, and thus it would make sense to choose 
RF_BLNK_Lyn over it. Based on these analysis the BLNK_Lyn random forest model would be the 
best choice to optimize the predictive strength of these bio markers. 
Table 4 :Integrated Brier Score for Cox and Random Forest Models
Time (months) 20 40 60 80 100
Reference 0.088 0.138 0.164 0.177 0.192
COX_all 0.122 0.154 0.178 0.199 0.236
COX_BLNK_Lyn 0.087 0.124 0.139 0.145 0.166
rf_all 0.069 0.106 0.123 0.136 0.151
rf_BLNK_Lyn 0.079 0.105 0.117 0.126 0.145
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Figure 12: Comparison of Potential Cox and Random Forest models.
Measurement of the average prediction error during 10 fold cross validation. Prediction error is 
calculated as the mean squared difference between the predicted probability of an event at time t and 
the status of a subject at time t. Predicted probability was compared for several BLNK SH2 based 
random forest and Cox models. RF_all and COX_all refer to models using all five of the SH2 domains. 
Lower predicted errors suggest a more accurate model. Reference model is Kaplan-Meier estimate of 
survival probability shown in Figure 7. 
2.5 Selection of SH2 domains for further investigation
To investigate the underlying biology associated with the models we just created, we sought to 
identify the best SH2 domain candidate for further study. In both model types BLNK appeared as the 
most important factor. In addition when looking at the random forest model, its contribution is less 
complicated (Figure 13). The threshold-like transition at 0.3 should allow for more straightforward 
biochemical investigation. Lyn, while still interesting, presents more of a challenge as its effect appears
to be more complicated due to the presence of a high mortality band for moderate levels of Lyn 
binding, whereas both high and low Lyn SH2 binding are associated with low mortality. 
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Figure 13: Partial Dependence Plots for RF_BLNK_Lyn model.
X axis represents the intensity of SH2 domain binding to the prepared clinical samples. Y axis 
(mortality) refers to the expected total number of events(as defined previously) for a given value of x.
2.6 Comparison of BLNK Binding threshold and IGHV mutational status as 
markers
To compare our BLNK marker to one of the current markers, IGHV mutational status, we split 
the dataset using the BLNK marker and compared the resulting survival curves. Samples were split at 
the 0.30 binding level identified in figure 13. For IGHV status, clinical data is split into three categories
(mutated, unmutated or polyclonal). Due to the fact that polyclonal IGHV status can be considered to 
represent an intermediate state (Crombie and Davids, 2017), we created separate curves with the 
polyclonal samples considered as either Unmutated or Mutated. Comparing these three curves (figures
14-16) and the associated p values, it appears that the BLNK marker performs better as a marker for 
risk of progression than the IGHV mutational status. 
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Figure 14: Survival Curves for High BLNK SH2 Binding and Low BLNK SH2 Binding Subjects
Subjects were split based on the 0.30 BLNK SH2 binding threshold. P value calculated with the log-
rank test.
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Figure 15: Survival Curves for IGHV Mutated vs Unmutated – Polyclonal as Unmutated
Samples separated by IGHV mutational status. Polyclonal samples were grouped with the Unmutated 
samples. Shaded region represents 95% confidence interval for the survival probability estimate. P 
value calculated with the log-rank test. 
2.7 Discussion and Future Directions
While cross validation can serve as a means for model evaluation, ideally it should not be used 
for such if the same data set was also used for the selection of hyper parameters. Since the random 
forest model does require a few hyper parameters to be set, it would be prudent to validate this model 
using an independent test set. With that in mind our lab is currently processing such a set of 25 new 
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Figure 16: Survival Curves for IGHV Mutated vs Unmutated – Polyclonal as Mutated
Samples separated by IGHV mutational status. Polyclonal samples were grouped with the Mutated 
samples. Shaded region represents 95% confidence interval for the survival probability estimate. P 
value calculated with the log-rank test. 
samples to be used for this purpose. In additional it would be beneficial to use these new samples to test
the later BLNK vs IGHV marker comparisons as well. 
In addition to the validation of the current model, it would be helpful to include additional 
existing data in the analysis. This data could be demographic, such as age or other existing markers. 
Potentially the inclusion of this data could allow for additional improvements to the performance of the
model. In addition it could yield insight into whether our new marker is actually acting as a surrogate 
marker for some other factor. Last it would allow for the better comparison of our new predictive 
model with some of the existing models or markers.
With the performance of the the BLNK marker, and the BLNK/Lyn-based predictive models, 
one can see the potential for SH2 domain based markers for CLL. It was particularly interesting to see 
the BLNK marker outperform the IGHV marker in our data. It is possible that the IGHV mutation 
status is more loosely associated with prognosis as it is also a marker of normal B-cell maturation, or it 
could also be too far upstream to capture different variations that may result in the same prognosis. 
Without knowing the true cause, one might speculate that the BLNK marker is capturing multiple 
disease states that result in poorer prognosis. If so, this could be attributed to the unique biological 
origin of the SH2 domains themselves. Endogenously, these domains can act as a way to sum 
phosphorylation signals from different proteins if their specificity is targeted towards phosphopeptides 
from these different proteins. Thus, an increase in phosphorylation in any one of these proteins would 
increase the local concentration of the SH2 domain containing protein and trigger downstream 
signaling. If a disease could be caused by a mutation in any one of these proteins or upstream of them, 
then the SH2 domain binding would increase regardless of the source of the driving mutation. 
When compared with genetics-based methods for identifying disease heterogeneity, SH2 based 
methods have the benefit of reduced dimensionality. In the case of gene array based methods, one 
challenge is the large number of genes. While it is possible to address this using computational methods
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(Santoro and Talbert, 2005), it results in non trivial additional steps. In addition to the reduced 
computational work, SH2 based methods have the potential for better sensitivity in certain cases. One 
plausible scenario, where a number of individual mutations can lead to the same change in SH2 binding
would result in better sensitivity for the SH2 based methods. To give a generic example: say a study has
10 patients and 6 suffer from a more aggressive form of the disease. This aggressive form can be 
caused by 3 different mutations that result in increased signaling through protein A. If these mutations 
occur evenly, with 2 patients having each mutation., then an individual gene in the gene array based 
method would only be able to identify 33% of the subjects with poor prognosis. When compared with 
SH2 based method that can read the phosphorylation of protein A, the true positive rate of 33% is not 
very good. Based on this simple example one might speculate that potential markers could be missed 
with these genetic methods, due to the potential lower frequency of individual mutations. This 
increased sensitivity due to signal aggregation could be the key to new improved markers that are better
suited to capture heterogeneities in disease states. Thus it would make sense to not only pursue SH2 
markers in CLL but in any disease where phosphotyrosine signaling is shown to play an important role.
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Chapter 3
3 Analysis of Peptide Binding interactions
Adam Lafontaine, Bruce Mayer and Kazuya Machida
Sections 3.3.1 and 3.3.2 were published minor formatting modifications in Bioinformatics
Author Contributions
AL designed and created Dynalogo. KM contributed to the design of Dynalogo and its documentation 




As established in the previous section, changes in BLNK binding sites (a subset of 
phosphotyrosine sites) are associated with a change in clinical outcomes. In order for a change like this 
to occur, a change needs to occur in the total quantity of these sites (protein expression), the fraction of 
sites that are phosphorylated (signaling change) or a change to the site itself which would change the 
strength of binding (mutation). To investigate possible underlying mechanisms associated with the 
BLNK Marker, one can narrow the field of possible proteins by looking at the binding sites for the 
BLNK SH2 domain. We sought out to reduce the number of possibilities by eliminating weak binding 
sites for the identified BLNK SH2 marker. 
In addition to a higher affinity to phosphotyrosines, individual SH2 domains show a preference 
to the amino acid sequences flanking the tyrosines. Knowing this preference allows one to ignore sites 
or whole proteins with the assumption that weaker binding sites are unlikely to be sites of interest 
associated with the change identified in the marker. For a similar change in binding site numbers, a 
poorly binding site would have a lower effect on the total bound amount of an SH2 domain. To identify
these preferred sequences we used a peptide binding array incubated with the various SH2 domain 
probes. In order to analyze this data we created a novel graphical tool for the visualization and analysis 
of the peptide binding array data. Then using this tool we were able to narrow down the list of possible 
proteins to candidates likely to bind the BLNK SH2 with the highest affinity. 
3.2 Methods
Custom peptide (Celluspot) arrays were manufactured by Intavis. They consisted of glass slides with 
spots of peptides covalently linked to cellulose (Wu and Li, 2009). Each array contained 384 peptide 
spots representing phosphorylated or unphosphorylated sites in the BCR signalosome selected from 
databases of known phosphosites. Initially two arrays were created with a total of 368 sites selected 
from a core of 38 proteins in the BCR signalosome (figure 17). The BCR signalosome refers to the 
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signaling complexes that form in response to antigen-mediated B-cell receptor crosslinking. The 
formation of these complexes can lead to downstream signaling outputs (Satpathy et al., 2015). For 
each site, seven amino acids before and after the tyrosine were included, resulting in peptides 15 amino
acids long.  These arrays were probed individually with 20 different SH2 domains fused with GST. 
They were then probed using a fluorescently labeled anti-GST antibody. The arrays were quantified 
using an Odyssey IR scanner and ImageStudio software (LI-COR Biotechnology) as shown in Figure
17. For  quantification, spots were overlayed with a 51 by 18 grid of spots. This grid would be aligned 
as a whole at first and if necessary, individual spots would be aligned to capture as much of the signal 
as possible. The size of the spots used in the software was 1.1202 (mm) in diameter. Within the 
software the background signal was calculated as the median value of the surrounding area for each 
spot. This was then multiplied by the area of the spot and subtracted from the intensity value to get the 
final signal. Spots with more than 5% of the pixels saturated were not included in the analysis. Once 
quantified, the data was processed in R to create a data table that could be analyzed using Dynalogo 
(Lafontaine et al., 2019). Sites with shorter sequences were padded with X to bring all the sequences to
a length of 15 with the tyrosine in the eighth position. Within Dynalogo, signals for nonphosphorylated 
sequences were subtracted from the corresponding phosphorylated version. 
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3.3 Dynalogo
Section 3.3 was published with minor formatting changes in Bioinformatics, Volume 36, Issue 5, 
March 2020, Pages 1632-1633, https://doi.org/10.1093/bioinformatics/btz766
Dynalogo: an interactive sequence logo with dynamic thresholding of matched 
quantitative proteomic data
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Figure 17: Example of Celluspot array and Quantification.
Slide B41 quantification using ImageStudio software. Slides contained two replicates which were 
quantified simultaneously using one array of quantification spots. The white handwritten A or B (A40, 




Current web-based sequence logo analyses for studying domain–peptide interactions are often 
conducted only on high affinity binders due to conservative data thresholding. We have developed 
Dynalogo, a combination of threshold varying tool and sequence logo generator written in the R 
statistical programming language, which allows on-the-fly visualization of binding specificity over a 
wide range of affinity interactions. Hence researchers can easily explore their dataset without the 
constraint of an arbitrary threshold. After importing quantitative data files, there are various data 
filtering and visualizing features available. Using a threshold control, users can easily track the 
dynamic change of enrichment and depletion of amino acid characters in the sequence logo panel. The 
built-in export function allows downloading filtered data and graphical outputs for further analyses. 
Dynalogo is optimized for analysis of modular domain–peptide binding experiments but the platform 
offers a broader application including quantitative proteomics.
Availability and implementation
Dynalogo application, user manual and sample data files are available at 
https://dynalogo.cam.uchc.edu. The source code is available at 
https://github.com/lafontaine-uchc/dynalogo.
Supplementary information
Supplementary data are available at Bioinformatics online.
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3.3.1.2 1 Introduction 
Peptide microarrays have been a popular high-throughput screening tool for mapping of domain–
peptide interactions that play essential roles in cell signaling (Liu et al., 2015; Tinti et al., 2013). Often 
researchers are interested in sequence preferences of binding sites, and a tool often used for visualizing 
these is the sequence logo. A sequence logo is a graphical representation, intended as an improvement 
over the consensus sequence. It displays the relative frequency of residues at each position for a subset 
of sequences (Schneider and Stephens, 1990). Currently several web interfaces exist for the use of this 
graphical display (Crooks et al., 2004; Thomsen and Nielsen, 2012). In addition to the standard logo, 
new approaches such as EDLogo and KPLogo can handle enrichment and depletion of sequences, as 
well as weighted sequences (Dey et al., 2018; Wu and Bartel, 2017). One potential drawback to 
currently available methods is that they fail to capture the continuous scale of binding interactions, 
because a threshold must be set, often selecting only high affinity ligands to reduce the chance of false 
positives (Shah et al., 2010; Tinti et al., 2013). Despite the simplicity of downstream analyses using 
only high affinity interactions, it is unknown if discarded modest interactions contain relevant 
information (Mayer et al., 2009). Our goal is to capture some of this information intuitively by 
allowing the user to adjust the threshold dynamically, and then visualize how this affects the 
appearance of the sequence logo. In this way, Dynalogo takes advantage of the weighted nature of the 
binding strength allowing the user to intuitively visualize binding specificities in a continuous way over
a wide range of affinity interactions. This can potentially provide insight into the relationship between 
affinity and specificity.
3.3.1.3 2 Approach 
Dynalogo is a web-based interactive application written in the R statistical programming language. It 
uses R Shiny for interactivity (Chang et al., 2019) and its dynamic nature with several other packages. 
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It is optimized for data obtained from peptide binding assays (e.g. microarrays, fluorescent 
polarization, etc.) using probes such as labeled protein interaction domains, antibodies and drugs. It can
also handle other quantitative proteomic data, provided they fit into the same data structure. Dynalogo 
outputs a Kullback–Leibler sequence logo using the ggseqlogo visualization package (Wagih, 2017). 
The Kullback–Leibler sequence logo provides a graphical representation of the enrichment and 
depletion of amino acids with background correction reflecting the prevalence of the different amino 
acids. A distinct feature of Dynalogo is its ability to dynamically change the threshold level and 
visualize the binding motif for a single or combination of probes. This is particularly useful when 
investigating the binding motif for a group of protein interaction domains or antibodies with similar 
ligand selectivity. As the threshold increases, any potential motif should increase in prominence until 
the sample size is no longer sufficient. In the case of SH2 domains, this gives the investigator insight 
into the types of sites that may see increased binding as an SH2 domain containing protein is 
overexpressed or local concentration increases. Furthermore, this could be generalized to identify the 
most likely binders for any domain of interest, yielding new signaling pathway hypotheses. 
3.3.1.4 3 Data exploration and visualization 
Dynalogo requires tabular data as a tab, comma or semicolon delimited file and will not work if the file
contains metadata. The data table should contain peptide ID, signal, sequence and probe (see 
Supplementary User Manual Section 2 (3.3.2.2). Once imported, data can be visualized in the 
Distribution Panel as an interactive chart including boxplot, histogram, or scatterplot. The scatter plot 
can be useful for comparing to subsets or replicates within the dataset, while the boxplot and histogram 
are useful to look at the general distribution of the dataset. These can also be useful for visually 
identifying skew in the data and whether a log transform might be appropriate. Once properly explored,
data can be further processed using the Data Summation/Thresholding Panel. This allows users to set 
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variables for averaging, filtering, normalization and thresholding. Thresholding can be based on the 
averaged signal or the z-score (a measurement of the distance of a value from the mean of the dataset). 
It can be manually adjusted by the user or auto-played with the threshold increasing periodically, 
allowing the user to see changes in the graphics as the threshold increases. These graphics consist of 
dynamic sequence logo (Dynamic Logo Plot), stacked barplot (Graph Panel) and digitalized raw array 
image (Digital Binding). The sequence logo will dynamically display the position-specific enrichment 
(positive values) and depletion (negative values) using the threshold slider (Fig. 11A and B). The Graph
Panel also allows for visualization of the data filtered using the threshold slider with an option to sort 
the x-axis ascending/descending, allowing users to quickly survey high/low affinity peptides in a 
waterfall type chart. A stacked version of the barplot can be used to identify common binding sites for 
multiple probes based on the stacked pattern (Fig. 18C). The Digital Binding allows the user to view 
their dataset in its original spatial configuration. Its interactive feature can be useful to reveal local 
outliers in a particular experiment. With utility during all points of the analysis, the Data Table is a tool 
meant to supplement all visualizations. It allows for the viewing and export of any dataset used in the 
application with various interactive features built in. The user can search for key words or sequences 
within the table allowing for further investigation from within the application. Raw or processed data 
can be downloaded as a csv for import into other tools. Thus, Dynalogo is not only a convenient tool 
for sequence analyses, but can be integrated into other proteomics pipelines (Matlock et al., 2015).
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3.3.1.5 4 Conclusion 
Dynalogo is an interactive web application which allows analysis using sequence logos and highly 
customizable data filtering. It can be used with peptide binding or other quantitative proteomic data. By
dynamically exploring the sequence logo at varying thresholds, users can visualize the consensus 
binding motifs for protein interacting domains at various affinity ranges. This type of analysis can also 
be useful for quantitative proteomics experiments focusing on motif enrichment associated with 
specific signaling network perturbations. Combined with the easy export feature, this showcases the 
versatility of Dynalogo as a new proteomics tool. 
3.3.1.6 5 Funding 
This work was supported in part by grants from the National Institutes of Health [U01 CA154966 to 
B.M. and K.M.], the Leukemia and Lymphoma Society [Quest for CURES grant R0818-14 to K.M.] 
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Figure 18: Core visualizations of Dynalogo. 
(A) Dynamic sequence logo with varying thresholds (from top to bottom: 1, 3, 6 for z-score). (B) 
Threshold slider. (C) Graph panel works with the slider allowing for visualization of the binding 
interactions over a wide range of affinities
and UConn Health [Health Center Research Advisory Council Exploratory Grant 401703 to K.M.]. 
Conflict of Interest: none declared.
3.3.2 User Manual
A full user manual was written and is included in the appendix, located in Chapter 6,page 84.
3.4 Selection of BLNK Interactors
Dynalogo was used to select the strongest binders for the five SH2 domains used in the CLL blood 
sample SH2 profiling study. Strongest binders were selected by isolating sites which had binding 
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Figure 19: Strongest Binders for BLNK and four other SH2 Probes.
Phosphosites identified with a threshold of 3.1 standard deviations from the mean of the corresponding 
SH2 domain. Binding signal was defined as the difference between the signal from the phosphorylated 
and non phosporylated versions of the site.
signals greater than 3.1 SD from the mean for that SH2 domain. Binding signals were defined as the 
difference between the binding for the phosphorylated and non-phosphorylated version of the site. 
Based on figure 19, sites on immunoglobulin alpha or PI3K may be good candidates for further study. 
For a broader selection, one could include sites which bind strongly to BLNK and only one other SH2 
domain (CD45, Dok1, SYK, Vav1). At the same time BCAP_513 may be less interesting as it binds 
strongly to most of the SH2 domains tested. 
3.5 Discussion and Future Directions
3.5.1 Application
While currently the application allows users to import their data and analyze it in a graphical and 
straightforward way, there are a few cases where if handled properly, the application could be enhanced
to allow the user to conduct more of their own data processing and reduce their need for a statistical 
programmer. One such case is the potential exclusion of data points. Allowing the user to selectively 
exclude data points would avoid an edge case where negative values prevent the use of the log 
transform. To avoid potential abuse of this feature, it may be better to set the log transform function to 
exclude these datapoints automatically and simply alert the user. Either way it would prevent what are 
quite possibly noise values from impeding the use of an existing feature. This could be beneficial for 
our own analysis as well. 
Additionally it could be beneficial to have another option for thresholding which utilizes 
percentiles instead of metrics based on the mean. This would allow the selection for the top x number 
of binders for a set of probes. With the current options, there is no way to consistently manipulate x and
it may vary from probe to probe if there is a large enough difference in their distributions. 
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Ideally with its current features, Dynalogo can be used by researchers without the need for 
programming skills. The ability to manipulate data quickly should reduce the time needed for initial 
analysis leaving more time for other work.
3.5.2 BLNK partner identification
As previously shown, higher BLNK SH2 binding is associated with better patient prognosis. In 
order to identify the mechanism underlying this association, it would be beneficial to have a list of the 
sites that bind to BLNK the strongest. This list of candidate sites could then be used to check against 
known mutations in CLL or other leukemias. An interesting possibility is the detection of a set of lower
frequency upstream mutations that would affect the number of binding sites for BLNK. This method 
offers the possibility to highlight similar acting mutations that, when alone, may occur in numbers too 
small to be significant. Another potentially interesting source of existing information, could be the 
expression levels for the proteins identified in the list within the diseased tissues of interest. This could 
allow for further reduction of the list or a better estimation of priorities. 
In addition, this list of candidates can be used for further biochemical experiments. While more 
cost intensive, it is possible to probe for these individual sites in patient samples through the use of 
phospho specific antibodies. This would allow for the positive identification of an individual 
phosphosite that is changing from sample to sample, though it may place a burden on limited stocks of 
clinical sample material. In addition it is possible that a change identified could be a result of an 
upstream change. What might be a better use for these samples is to use them to collect the genetic 
information that would be interesting to compare with the SH2 binder data. Knowing the mutations that
occur in the different samples in our study could help to connect potential driving mutations to our 
identified binding partners. While it is possible that a mutation could have a direct effect on the binding
site, by converting a strong BLNK binder to a weak one, the more likely scenario, is that mutations 
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upstream are indirectly affecting binding site abundances through changes in phosphotyrosine levels. 
For this scenario, it could be useful to create a map that represents the degrees of separation between 
potential mutations and the identified SH2 phosphotyrosine interactions. A protein that binds directly to
a phosphosite would be the first level. A protein which interacts with a scaffolding protein in the middle
might be considered on the second level. Identified mutations could be checked against a map like this 
and prioritized for their likelihood to be related to our SH2 based marker.
When combined with the identification of SH2 domains as markers, identifying the 
corresponding binding partners offers a way to connect different signaling proteins with a marker 
shown to represent disease heterogeneity. As phosphotyrosine signaling plays a role in a number of cell
fate decisions, this could be applicable to a number of different diseases. In addition, because it offers a
way to link different mutations to the same downstream mechanism or effect, it could pick up on 
mutations that occur too infrequently to be of statistical significance on their own. 
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Chapter 4
4 Modeling of BCR Signaling Pathway
Adam Lafontaine, Pedro Mendes, Ion Moraru, Michael Blinov, Bruce Mayer
Author Contributions
AL created VCell models and contributed to the writing of this chapter with BM contributing revisions 
and suggestions. In addition the modeling work was guided by input from IM, PM and MB.
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4.1 Introduction
As mentioned previously, the list of strong BLNK binders would be a start for the further 
investigation of the underlying biology. One way to continue with this investigation is through the use 
of mechanistic modeling of the BCR signaling pathway. Once implemented, mechanistic models can 
have a number of beneficial uses. In general, mechanistic models can be used to understand the why or 
how of a correlation found in a statistical model. By representing the individual proteins and pathways 
they can allow for a more detailed investigation of the system. They can be used to generate new 
hypotheses, or to test existing ones. Often running a model is more cost-effective than running an 
experiment, and thus therapies or drugs can be screened in large quantities to reduce the number of 
experiments necessary. Models can also be a place to test new mechanisms or to challenge 
assumptions. One can compare models with and without a potential modification to see if it is feasible, 
or remove an existing mechanism to check whether it is important in producing the observed responses.
Thus the use of a mechanistic model would aid us in the investigation of the underlying signaling 
associated with the marker identified in Chapter 2.
For our work we are particularly interested in the use of modeling for the investigation of the 
BLNK marker and the identification and screening of potential new drug targets. With a completed 
CLL BCR signaling model, we can test the proteins identified in the binding assay analysis, in silico, to
select only the most promising for further biochemical experiments. These experiments can then be 
used to refine the model to better capture the underlying signaling associated with the BLNK marker 
and the differences in patient prognosis. This refined model could then be used to identify potential 
drug targets for the different risk groups through the use of sensitivity analysis. In addition, existing 
drugs could be tested in silico using the signaling parameters for the different risk groups. In general 
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this model would ultimately serve as a way to connect the changes in SH2 profiling data with changes 
in individual molecules that could later be targeted for therapies. 
In order to create an such a model, we could either build a model from scratch, or choose to 
adapt an existing model for our use case. While building a new model from the ground up is a 
possibility, it is wise to avoid it if similar models exist. One reason for this is the time it can take to 
curate or collect the data necessary to parameterize the model. In addition, building off existing models 
not only uses the work of others but allows for additional validation of those existing models. Thus, in 
efforts to create our own mechanistic model of BCR signaling we reproduced two existing BCR 
signaling models. Ideally they would model signaling events in the BCR signalsome from initial 
receptor binding to the activation of cell fate influencing pathways like ERK, NFκB and AKT. Once 
validated, we could combine these models and use the final model to perturb proteins upstream of our 
potential marker to better understand the mechanistic impacts of such changes and potentially identify 
drug targets. 
Both of these models were originally developed in MATLAB, a mathematical program for 
general purpose modeling. MATLAB is a popular tool due to its flexibility and its acceptance within 
the engineering and physical sciences. With its use, however, comes the necessity to explicitly track 
mass conservation within the model, a task which can be difficult with larger models. This is one 
reason why software packages like COPASI (Hoops et al., 2006) and VCell (Schaff et al., 1997), which
have been designed to ensure mass conservation is followed, can be a better choice for creating 
mechanistic models. With that in mind, it becomes harder to justify the use of MATLAB unless the 
flexibility is desired or a previous model requires it. In addition, MATLAB-based models can be 
difficult to reproduce or validate, due to differences in versions and license requirements. VCell (Schaff
et al., 1997) and COPASI (Hoops et al., 2006), however, are free to use and work with standards like 
systems biology markup language (SBML) (Hucka et al., 2003). SBML is a software independent-
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language for the specification of computational biology models allowing for the interoperability of 
models between various software packages (Hucka et al., 2003). This allows the movement of models 
between software packages, enabling the user to take advantage of features in multiple software suites. 
A VCell model can be imported into COPASI, where we could eventually take advantage of tools like 
sensitivity analysis. Another benefit of VCell is that it has the built-in functionality to share models and
reference them for publication, allowing for easier validation by other researchers. With that in mind 
we set out to translate two existing MATLAB models into VCell in order to take advantage of these 
various benefits. 
The two models, by McGee (McGee et al., 2015) and Du (Du et al., 2017), utilize ordinary 
differential equations (ODE). ODEs allow the modeler to specify the rate that the concentration or 
amount of a molecule will change. Mass action kinetics, which is used by the McGee model (McGee et
al., 2015), represents these rates as being proportional to the product of the concentrations of the 
involved species. The Du model utilizes a combination of Michaelis-Menten kinetics; for the 
phosphorylation reactions, and analytically solved steady state equations; for the protein-protein 
binding interactions (Du et al., 2017). The McGee model contains 22 species with 32 ODEs. The Du 
model contains 15 ODEs and 10 steady state equations. 
While both models include B-cell receptor (BCR) signaling, the two models differ in the 
specific pathways and molecules they include. The McGee model, while containing more detail 
regarding BCR activation, lacked pathways of importance like the AKT pathway and SH2 domain 
containing proteins like PI3K. This is not entirely surprising as the McGee model was created to 
specifically investigate the effects of modifying SYK activity (McGee et al., 2015). The Du model was 
created with the ultimate goal of linking it to a tumor growth model, and contains the AKT pathway 
and the molecule PI3K. Both models contain the NFκB and Erk pathways. Traditionally the Erk, AKT 
and NFκB pathways are associated with proliferation (Shapiro, 2002), survival (Song et al., 2005), and 
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inflammation (Liu et al., 2017) respectively. In addition to their connection with various cell fate 
outcomes, these pathways have also been found to be of interest for the study of CLL (Ghosh and Kay, 
2013; Lopez-Guerra and Colomer, 2010; Schrader et al., 2014). Thus it is important to consider these 
pathways when comparing available models. 
In addition to the differences in the signaling molecules and pathways, these models differ in 
the type of data they were fit to. In the McGee model, parameters were established using novel data 
from chicken DT40 B-cells while the Du model used existing data from mouse A20 B-cells (Kumar et 
al., 2007). While both are B-cell lines, the Du model utilizes a mammalian cell line, which would be 
preferred when trying to adapt it to fit human disease. 
4.2 McGee Model
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Initial modeling began with the McGee model (McGee et al., 2015) and once reproduced this 
allowed for some initial pilot experimentation. This model was reproduced in VCell and the 
simulations and analysis were conducted in that software. While recreating the model we found a few 
places where it was necessary to modify the MATLAB model we used to benchmark our model. The 
first place was how non phosphorylated BLNK was calculated. This is important for the reaction where
SYK342 phosphorylates BLNK, 
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Figure 20: Diagram of McGee Model reproduced in VCell.
VCell implementation of the model described in McGee et al. Model is initiated when ligand binds to 
the BCR resulting in receptor aggregation and phosphorylation (A). Phosphorylated BCR complex 
binds SYK allowing it to become phosphorylated (B). Phosphorylated SYK phosphorylated BLNK. 
Phospho-BLNK binds to BTK, PLCγ and SOS. Once bound, these three can be phosphorylated or 
activated. Signaling activity can result in the activation of the Ras pathway (D) and/or the NFκB 
pathway(E). This model can be accessed within the VCell software (available at https://VCell.org) 
“McGee_2015_01-04-20” by user “alafontaine”.
SYK 342+BLNK→ SYK 342+BLNK phos
where the rate is calculated using the concentrations of SYK342 and unphosphorylated BLNK.
dBLNK phos
dt
=k f∗SYK 342∗(BLNKunphosphorylated )
The issue arises in how unphosphorylated BLNK is calculated. In the MATLAB code it is calculated as
BLNK unphosphoylated=BLNK total−BLNK phos  
however there are several species in the model that are actually complexes of phosphorylated BLNK 
and another molecule. Thus to include all phosphoylated BLNK in this calculation the formula should 
be BLNK unphosphoylated=BLNK total−BLNK phos−BLNK bound where BLNK bound represents these 
complexes BLNK bound=PLCgphos+ PLCgbound+Btk phos+Btkbound+SOSbound . Thus in order to accurately 
represent mass conservation, the MATLAB model was modified to reflect the latter definition of 
unphosphorylated BLNK. This highlights one of the benefits of using a modeling package like VCell or
COPASI as it enforces the proper tracking of mass conservation.
The other change was to modify the BTK phosphorylation reaction to better match what is 
described in the paper. The original equation
dBTK phosphorylated
dt
=k forward∗Lynactivated∗(BTK total−BTK phosphorylated−BTKbound )−kreverse∗BTK phosphorylated
represents the phosphorylation of BTK by Lyn and the associated the reverse reaction. The problem is 
that this equation uses nonphosphorylated unbound BTK as the substrate for the phosphorylation. 
Within the text of the paper the reaction is described as the substrate being BTK that is bound to 
phospho-BLNK. This would agree with the mechanisms described in other papers, where BTK must be
bound to BLNK before it can become phosphorylated (Du et al., 2017). Thus this equation was 
modified both in the VCell and MATLAB models to match both the mechanism as described in both 
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the McGee and Du papers. This was found during the model validation process and highlights one of 
the benefits of reproducing and validating a model like this.
In the process of rebuilding the model in VCell, the units of many of the parameters were 
converted. The units in the MATLAB based model were in number of molecules and the units of the 
VCell model were µM. For this conversion all parameters in units of molecules were divided by 















conversion was applied to all parameters with units of molecules or 1/molecules and the values for 
these parameters were left with the expression unsimplified to make this easily recognizable (table 5). 
Table 5 Examples of Modified Parameters
To convert parameters in units of molecules, parameters were divided by (602*498). For parameters 
with units of per seconds per molecule, this value was multiplied by (602*498). Additional parameters 
can be found within the public VCell model. With the exception of BLNKtotal, rw15_kf and rw15_kr, all 
parameters in the model should contain the conversion unsimplified for increased clarity. These three 
parameters were required to have a simplified form in order to run the parameter scans. For additional
parameters, please see the shared model described in that caption of figure 20.
Parameter Name Original Value (MATLAB) VCell Value
Erktotal 170220 (170220.0 / (602.0 * 498.173364330786))
rw18_kf 10^(-5.90348548130226) ((10.0 ^  - 5.90348548130226) * (602.0 * 
498.173364330786))
BLNKtotal 50000.0 (50000.0 / (602.0 * 498.173364330786))
rw15_kf (10.0 ^  - 5.7437477821138) ((10.0 ^  - 5.7437477821138) * (602.0 * 
498.173364330786))
rw15_kr 6.801E-5 (6.801E-5 * (602.0 * 498.173364330786))
Once validated to accurately reproduce the original, the McGee model would be readily 
accessible in a convenient platform where we could add new species and pathways to better represent 
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the CLL disease state and our SH2 binding data. To validate this model, we compared the published 
results with the results produced by the VCell and MATLAB models (Figure 21). Specifically, time 
courses from VCell and MATLAB models were compared with the published time courses for 
phosphorylated Erk and non degraded IκBp (Figure 21). In addition the time courses for all of the 
nodes were compared visually between the modified MATLAB model and the VCell model. Between 
the two models, all of the max values were found to be within less than one percent. This suggested 
that the VCell model was capable of reproducing the results of the modified MATLAB model. 
After validation, we used the VCell model to test how large of an effect BLNK SH2 binding 
interactions could have on downstream signaling and the outputs of the pathway. This test was 
conducting using parameter scans for the constants governing SYK activity, Shp1 activity, and the total
concentration of BLNK. For each constant or parameter, the simulation was run with values for that 
parameter ranging from two orders of magnitude above to two orders of magnitude below the current 




Figure 21: Validation of McGee Model in VCell. 
From left to right, a comparison of figures from the paper with output from VCell and 
the original MATLAB model. Comparison was conducted for Phosphorylated Erk(A) 
and Non Degraded IkBp(B).
Scans were conducted for parameters expected to affect the amount of BLNK activity in the 
model. Since the model does not explicitly include BLNK binding interactions, BLNK activity was 
chosen as a proxy to manipulate. In the model, active BLNK (phosphorylated BLNK) is affected by the
kinase SYK, phosphatase Shp1, and the initial concentration of BLNK. Results from these scans 
showed (Figure 22) that varying SYK activity (a) and initial concentration of BLNK (c) had an effect 
on the kinetics of the fraction of phosphorylated Erk and the amount of NFκB. In addition, varying 
these parameters had an effect on the equilibrium value for NFκB. More importantly, despite the fact 
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Figure 22: Scan of parameters expected to influence BLNK 
activity. 
Parameters were scanned 2 orders of magnitude above(green) and 
below(red) the values defined in McGee et al.(purple) A) Varying SYK 
activity for phosphorylating BLNK affects the fraction of phosphorylated 
Erk and amount of NFκB. B)Varying Shp1 Activity has no visible effect 
on phosphorylated Erk or NFκB. C) Varying initial concentration of 
BLNK affects the fraction of phosphorylated Erk and amount of NFκB.
that it influences many nodes in the model, varying the activity of Shp1 (Figure 22 panel b) did not 
have an effect on these indicators of downstream activity. This illustrates the importance of mechanistic
modeling, as a relationship like this would not be apparent by looking at the reaction network alone. 
These initial results suggest the ability to affect cell fate markers (phosphorylated Erk, NFκB) through 
the manipulation of factors affecting BLNK activity and re-emhasizes the importance of mechanistic 
modeling in investigating the effects of perturbing individual molecules.
In its current state, the McGee model would only serve as a starting point for our potential CLL 
model. It is limited because it lacks some SH2 domain containing proteins and important pathways. To 
modify the McGee model it would be necessary to add PI3K and the associated AKT pathway. PI3K is 
important because it is one of our SH2 domain containing proteins and also because it is an important 
component of the BCR signaling pathway. Furthermore, PI3K inhibitors have been investigated as 
potential therapies for CLL (Ortiz-Maldonado et al., 2015). 
4.2.1 Du Model
In addition to the McGee model, a second model by Du et al. (Du et al., 2017),was identified to 
be suited for our purposes. When compared with the McGee model, this model was more complete in 
relation to the desired proteins an pathways. It included PI3K and the AKT pathway. In addition, this 
model had an existing cell fate layer, connecting the final pathway outputs with cellular level outcomes.
The model systems used to develop the model were also more appealing with the signaling model fit to 
data derived from a mouse derived B-cell line and the cell fate layer fit to data from Human Diffuse 
Large B-cell Lymphoma cell lines (Du et al., 2017). 
Due to the way it was implemented in MATLAB, there were several challenges adapting the Du
model to work in VCell. The majority of these challenges were associated with the analytical solutions 
used for the binding reactions. As stated in the paper, the binding reactions were assumed to be fast and
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thus an analytical solution for equilibrium could be used. In our VCell model, this was reproduced by 
by using stiff parameters for the forward and reverse binding reactions. We initially set the forward 
reaction rate constants to represent association constant Ka  which is equal to 
k forward
k reverse
. By setting 
the forward rate to Ka  and the reverse rate to 1, we could achieve the same equilibrium values. This 
did not however make the transition quick enough and to adjust we increased both forward and reverse 
reaction rates by 5 orders of magnitude, increasing the stiffness. This left the Kd unchanged, but would 
increase the rate these reactions would reach equilibrium. At a high enough stiffness, the results would 
approximate the analytical solutions used in the paper. 
In addition it was necessary to include a reaction for the unbinding of a protein if its partner 
became unphosphorylated. This was the case with the interaction between phospho-BLNK and BTK. 
The necessity of this reaction is due to the fact that the original MATLAB model does not differentiate 
between phospho-BLNK that is bound or unbound but only tracks a general pool of phospho-BLNK. 
The challenge arises in our rules requirement of BLNK to be phosphorylated to bind to BTK. With the 
rule based model, the bound and unbound forms will both be tracked and there will be a molecule 
where BLNK becomes dephosphorylated while still being bound. With the simple pool of phospho 
BLNK this species would never occur due to the binding reactions being defined as fast equilibrium 
reactions. If phosphorylation levels drop, there is a new binding equlibrium in the next step. Thus we 
added a fast disassociation reaction to occur when BLNK is dephosphorylated. 
Another assumption of the paper was that the binding interactions were all independent, even if 
one species bound multiple partners. This proved challenging for two reasons, one technical and one 
associated with reproducing biologically improbable kinetics. The technical challenge arose with the 
use of rule based modeling (see section 1.6) a technique useful the handling of independent binding 
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sites on a protein (Figure 23). While particularly useful for implementing molecules with independent 
binding sites, complications arose with implementation of the phosphorylation kinetics. In the original 
model, catalytic reactions were represented with Michaelis-Menten kinetics. Unfortunately these could 
only be implemented manually when using rule based modeling in VCell. This required changing the 
reaction and parameters for all of the generated reactions associated with the rules, eliminating some of
the benefits of rule based modeling. To overcome this, we created a script to programmatically make 
these changes after the generation of the flattened network (figure 24). The script was written in Python
to read and modify the exported VCell file. In addition to setting the Michaelis-Menten kinetics, the 
script was also used to set several output variables for later visualization. 
The second major challenge arose when reproducing the kinetics of BTK. For this, the script 
was necessary to create artificial quantities for the amount of bound BTK. This artificial quantity was 
required in order to exactly replicate the kinetics in the original MATLAB model. This is due to the fact
that BTK could be either recruited by phosphorylated BLNK or PIP3 (Figure 23). While the 
independent binding can be represented by rule based modeling as binding with different sites on BTK 
(Figure 23), this would result in the possibility of some amount of BTK bound to both BLNK and 
PIP3, which is not accounted for in the original Du model. To accurately represent the amount of bound
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Figure 23: Example of binding in the rule based model. 
Black lines represent potential binding interactions between phosphosites and 
SH2 domains. BTK can bind BLNK or PIP3 via its SH2 domains. BLNK can 
bind BTK or PLCγ via its phosphotyrosines.
BTK (BTKb) when the two molecules bind to independent sites on BTK, one would have the following
equation. BTK b=BTK BLNK+BTKPIP3+BLNK BTKPIP3 . Unfortunately within the original model, the 
quantities are treated as if BTK BLNK  and BTK PIP3  are two distinct complexes and that there is no 
possibility of BTK binding to both simultaneously. Thus the amount of bound BTK is represented as
BTK b=BTK BLNK+BTK PIP3 . To accurately replicate the original model, the rule based model had to 
be modified so bound BTK reflected the second equation, circumventing VCell’s mass conservation 
protections. This was implemented by creating a separate global variable to represent bound BTK as it 
would be calculated in the original Du model. This variable was then used for all calculations that 
required the concentration of bound BTK (i.e. BTK catalysed phosphorylation). While this breaks the 
enforcement of mass conservation of the RBM and causes the model to less accurately reflect the 
biology, it does allow us to accurately replicate the original Du model in VCell, an important step 
towards the creation of our own model. To make these modifications we ran the python script to 
modify an exported version of the flattened model. 
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Due to the complexity involved in accurately reproducing the original model, we added nodes 
individually with a validation step between each one. This allowed for the necessary troubleshooting 
involved with the VCell model, python script and three VCML files. After the adding of a new node, 
the kinetics for that node and potentially others affected by it were compared to the values from the the 
original model. To prevent unfinished downstream nodes from affecting the section we were working 
on, we removed the feedback affecting BTK. This was done by setting the equations for bound PKC 
and PIP3 to constant values. This modified MATLAB model was used for all of the completed 





























Figure 24: Workflow for Modification of RBM with Python Script.
Initial rule based model (RBM) is flattened yielding a biomodel with all of the 
possible reactions and species. This biomodel is then modified by the python script
using settings from both the RBM and flattened models. Once modified, the script 
yields a new flattened biomodel which can then be simulated for analyses. 
validated, the modification will be removed and the original model restored. Currently the Du Model 
has been translated to include the kinetics for SYK, Lyn, BCAP, CD19, BLNK, BTK, PLCγ2 binding 
and SHIP (Figure 25, see (Vasilescu et al., 2018) for notation). When flattened, this results in a model 
with 526 reactions and 77 species. The VCell model files and script are available on GitHub using the 
following link (https://github.com/lafontaine-uchc/BCR-RBM-V  c  ell-Modification-
Script/tree/thesis_2020/python-sbml-script). All previously described modified parameters can be 
found in the Rull-based VCell model or the python script.  
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With the addition of each new species, the model has been validated against the original to match the 
max value and the time to max value for the species within a few percent. Examples of this validation 
can be seen in figures 26-29.
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Figure 25: In progress rule based model of BCR signaling based on Du et al.
This model is constructed of phosphorylation dependent binding rules (b, g) and enzymatic rules (a, c, 
d, e, f, h, i). B-cell Receptor activation is represented by transient increases in the amount of pSYK and 
pLyn. pSYK then phosporylates BLNK and BTK (a, e). Phosphorylated BLNK (pBLNK) functions as an
adapter protein binding with both BTK and PLCγ in a phospho dependent manner(b). A similar 
reaction occurs with PIP binding to BTK(g). Once bound, BTK and PLCγ are available to be activated 
as enzymes. Initial enzyme activation occurs as pSYK phosphorylates BCAP, BTK.PIP and BLNK.BTK 
(d) and Lyn Phosphorylates BTK.PIP, BLNK.BTK, CD19 and SHIP (e). Once phosphorylated BTK can
phosphorylate BCAP (h) and PLCγ (c). Dephosphorylation in the model occurs either resulting from 
specific phosphatases like ptp1b (f) or from general phosphatase activity (i). This figure was created 
with the help of M Blinov and the notation is described in Vasilescu et al.
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Figure 27: Validation of BTK Dynamics. 
Concentration of phosphorylated BTK as output from VCell model (a) and original MATLAB model 
(b).
Figure 26: Validation of SHIP dynamics. 
Concentration of phosphorylated SHIP as output from VCell model (a) and original MATLAB 
model (b).
4.3 Discussion and Future Directions
Initial parameter scans with the McGee model demonstrated the potential for investigating related 
dynamics to an SH2 domain of interest (BLNK). However in its current form the McGee model is 
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Figure 29: Validation of pBCAP Dynamics. 
Concentration of bound pBCAP as output from VCell model (a) and original MATLAB model (b).
Figure 28: Validation of PLCγ Dynamics. 
Concentration of bound PLCγ as output from VCell model (a) and original MATLAB model (b).
insufficient for our desired application. It lacked several of the SH2 domains of interest and lacked the 
AKT pathway. With its various benefits over the McGee model, we plan to continue implementing the 
Du model and eventually adapt it to our needs. The Du model is not without challenges, as it required 
workarounds to the safeguards in VCell in order to reproduce it properly. Once validated, we plan to 
test some of the assumptions made by the original model and simplify the resulting VCell model. First 
simplifications can be made with existing parameters to see what type of an effect they might have. 
This can be useful information for later justification of the inclusion or exclusion of a mechanism. Most
likely some changes will have an effect and it will be prudent to refit the model to the original dataset. 
Once refit, the resulting model would need to be validated against new data, most likely from a similar 
cell line. Once validated it would be interesting to compare predictions from the model to responses in 
CLL cell lines. This can also be combined with perturbations with existing drugs to further constrain 
the model. When responses differ, the model can be modified to try to capture any missing mechanisms
or parameters to accurately reflect the disease cell lines. This iterative process can be used until the 
model is capable of reproducing the cell line of interest. Most likely different cell lines may require 
different parameter sets or potentially different mechanistic structure due to disease heterogeneity, but 
this should shed additional light into the underlying mechanistic differences associated with these 
disease states. It may also be interesting to compare the model with cell lines of similar B-cell 
lymphomas like DLBCL. This may allow the model to better reflect disease heterogeneity as there 
appears to already be connections between several of these lymphomas. CLL has been shown in a few 
percent of cases to transform into a more aggressive lymphoma like DLBCL (Parikh et al., 2014), so 
enhancing the model to capture this may be beneficial. In addition to the better representation of 
underlying mechanisms, changing some assumptions, like the independence of binding to instead allow
competition between binding proteins could eliminate the need for multiple sites within a molecule and
should reduce some of the combinatorial complexity. With the validated models we can again run 
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parameter scans around the SH2 domains of interest, BLNK and potentially Lyn. Though individually 
Lyn was not indicated as significant, its inclusion in both the Cox and random forest models appeared 
to reduce error (Figures 9 and 11). By perturbing different nodes upstream of BLNK, we can identify 
upstream proteins which may contribute to the BLNK SH2 binding signal. In at least some cases, these 
proteins should correspond with the strong binders identified by the binding assay data. 
In addition to the more traditional signaling models, achieving our goal of understanding our 
SH2 domain marker will require the ability to translate signaling model outputs or phosphosite 
abundances into SH2 binding signals. Unfortunately this is not a simple problem, due to the fact that 
SH2 domains can bind to a number of different proteins with different affinities. Thus an SH2 binding 
signal is likely to be a combination of signals from different phosphosites on different proteins. To 
translate the model-level data to SH2 domain binding levels, one could use SH2 binding data from the 
same signaling state as the other data used for the model. This would be reasonable to attain during the 
validation steps with the various cell lines as it would represent a few more probings of existing cell 
lysates. With this data, one could actually fit a secondary layer of weights for the different proteins or 
phosphosites in the model. These weights would represent the contribution of these sites or proteins to 
the overall binding signal of a specific SH2 domain. Biologically these weights should represent a 
combination of the effects of the abundance and affinity of the sites. Conversely one could try to create 
this layer by combining information from the Celluspot binding assay with data on phosphosite 
abundances. Ultimately, for either approach, between the creation of the layer and validation, one 
would need to have SH2 binding and phosphosite level data in order to properly connect the SH2 
binding levels to the current model output. Due to the challenge with the amount of clinical sample 
material available to collect SH2 profiling and individual phosphorylation data, the creation and 
validation of this layer will have to occur with the use of various CLL or other B-cell lymphoma cell 
lines.
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With the creation of this SH2 model layer, one can directly match SH2 binding profiles with 
different CLL signaling states and test mechanistic perturbations for particular states of interest. This 
would allow the simulation of potential interventions based on the SH2 binding levels and the 
identification of ideal treatment plans for the different patient subpopulations. Also by identifying the 
pathway responsible for the changes in BLNK SH2 binding sites, one could potentially identify new 
drug targets or new candidates for improved biomarkers.
By combining this mechanistic model with the statistical model, we can really start to explore 
the whys underlying the relationships identified by the statistical model. Ultimately the better 
understanding of the why can lead to better clinical outcomes in the long term, as it allows us to pose 
and test hypotheses about potential treatments and individual mechanisms responsible for disease 
heterogeneity. With the SH2 domains and binders identified in earlier chapters, we can build this model
with these in mind to ensure we have appropriate parameters and mechanisms that can be manipulated 




5 Summary & Discussion
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With the goal of finding better markers for CLL, SH2 profiling is a promising new technique 
for investigating this disease. SH2 profiling has already been shown to be a powerful tool for tumor 
classification and biomarker identification (Machida et al., 2010). In addition the technique itself offers
several benefits associated with its origin in the endogenous signaling biology. With the probes based 
on the endogenous machinery for the reading of tyrosine phosphorylation, the method both conveys an 
unmatched coverage of the signalosome along with biological meaning due to the domains connections
with the signaling pathways they are normally a part of. These very same pathways also contain the 
targets of several existing therapies for the treatment of CLL. Thus SH2 profiling can be a promising 
tool for the investigation of CLL signaling.
While useful, SH2 profiling presents a unique challenge due to the characteristic specificity of 
the SH2 domains. With the ability to bind to varying phosphosites with a range of affinities, 
interpretation of the signal associated with these domains can be a challenging task. While it is possible
to identify clusters of interesting samples using unsupervised methods, connecting SH2 binding 
patterns with subgroups of patient outcomes is well suited for supervised machine learning or statistical
models. While often useful for predictions, statistical models do not reveal much about the mechanistic 
changes underlying the identified differing disease states. At best they can identify an SH2 domain of 
interest but no further. In order to further investigate the underlying biology additional models or 
experiments are needed. These experiments or models should identify the proteins and pathways 
involved in the signaling changes.
To investigate the underlying biology associated with potential disease state changes, we 
implemented a combination of statistical and mechanistic models along with binding assays to create a 
workflow for systematically identifying progressively detailed changes in the underling signaling. The 
use of statistical modeling, allows for the construction of a predictive model, and the identification of 
important SH2 domains for the predictive qualities of that model. These SH2 domains are the first clue 
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in understanding the differences in the underlying biology. From there we utilized a phosphosite-SH2 
binding assay to identify the strongest binding sites for this SH2 domain and prioritize sites for further 
investigation. Taking advantage of existing B-cell signaling knowledge, we implemented mechanistic 
B-cell signaling models. These models can be used to predict the effects of manipulating molecules 
identified from the binding assay or other molecules further upstream. Once identified, these sensitive 
molecules can be targeted for further study or as potential drug targets. 
Individually each section in this workflow has improved the state of the field in some way. In 
the second chapter, comparisons of the BLNK marker with the IGHV mutational status, suggest that 
BLNK alone performs better than the existing marker. When combined with the fact that the BLNK-
Lyn predictive models, specifically the random forest, perform better than BLNK alone, one can 
suggest that there is additional improvement over the existing IGHV marker. In chapter three we 
created a novel open source tool for the binding array dataset, allowing researchers applying this 
workflow, to more quickly explore and analyze their own datasets. In chapter four, we translated 
existing MATLAB based BCR signaling models into VCell, validating them in the process. This has 
made these models more accessible and has identified several questionable assumptions for future 
discussion. Thus, not only does this workflow as a whole present a novel approach to the investigation 
of clinical SH2 profiling data, but the individual components each represent novel contributions to their
respective fields.
This workflow presents a unique way to progressively work from the pathway level with the 
SH2 binding data to the identification of individual molecular changes driving the biological changes. 
While only discussed in the context of CLL, it could be applied to the study of a number of different 
diseases. A few quick examples could be other B-cell malignancies and autoimmune disorders. Both 
have been shown to have BCR signaling playing a critical role (Puri et al., 2013). In a more general 
fashion, this workflow, could be applied to any disease where tyrosine kinase signaling is of interest. 
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This is largely due to the fact that it is based on SH2 profiling, a technique inspired by and developed 
from tyrosine kinase signaling machinery. With the involvement of tyrosine kinase signaling in a 
number of diseases, this could expand its reach to other cancers and autoimmune and inflammatory 
disorders (Szilveszter et al., 2019; Ma et al., 2017). Most likely the main limitation for this technique 
will be the collection of clinical tissue samples. While the initial collection of clinical samples may 
prove challenging for auto immune disorders, it has already been shown for blood-based and solid 
tumors (Machida et al., 2010, 2012). 
Overall, this workflow provides a novel method for both generating new markers and 
investigating the underlying mechanistic differences between disease states. 
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6 Appendix
6.1.1 Dynalogo: an interactive sequence logo with dynamic thresholding of 
matched quantitative proteomic data – User manual
Dynalogo is optimized to visualize and explore quantitative peptide sequence data, typically with 
modular domain–peptide array binding experiments (Engelmann et al., 2014; Tinti et al., 2013) and 
possibly with quantitative mass spectrometry analyses (Schlage et al., 2015; Soufi et al., 2009; Stoehr 
et al., 2013). The app will provide dynamic visualization of sequence logos for better insight into the 
relationship between the affinity and specificity of binding domains. Once imported, the data can be 
visualized in several different ways: 
● Dynamic Logo plot- a reactive implementation of ggseqlogo and Seq2Logo (Thomsen and 
Nielsen, 2012; Wagih, 2017) 
● Graph – binding signal vs binding site/sequence 
● Distribution – binding signal visualized as boxplots, scatterplots or histograms 
● Digital Binding Array – recreation of experimental layout of data 
6.1.1.1 1. Technical Descriptions and Resources
6.1.1.1.1 1-1 Implementation 
Dynalogo is an interactive application written in the R statistical programming language. It uses R 
Shiny for interactivity (Chang et al., 2019) and its dynamic nature with several other packages for 
specific reactive features. The core visualization packages are ggplot2 (Wickham, 2016) and plotly 
(Sievert, 2018)for the charts and figures with ggseqlogo (Wagih, 2017) for creating the actual sequence 
logo visualization. The calculation of the heights in characters for the sequence logo visualization is 
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described below and is based on the Kullback-Leibler logo as described by (Thomsen and Nielsen, 
2012). General data manipulation uses functions from the tidyverse set of packages. 
Dynalogo can be run using the source code referenced above from within RStudio or deployed 
on a shiny server. To ensure compatibility, the user can download the current list of packages and 
Version numbers from the Dynalogo website by clicking on the "Version Info" text at the top of the 
application located at dynalogo.cam.uchc.edu. If running on a shiny server, the user must ensure that 
the temp folder has the permissions set so the shiny user (or the user under which the shiny server is 





Source code: https://github.com/lafontaine-uchc/dynalogo 
6.1.1.1.2 1-2 Data Processing
The Diagram below shows the data processing flow in Dynalogo. Once data is loaded it undergoes 
various processing steps and (depending on the desired visualization) may represent different stages in 
this process. To look at the data used to produce any figure, the user can export the dataset from the 
data table by selecting the name in blue associated with that visualization. For the Logo plot, two 
datasets are used and are specified in the diagram. The diagram also features the internal variable 
names for the various stages. For most users these internal names will never be used, but they could be 
helpful for individuals trying to follow the source code. 
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6.1.1.1.3 1-3 Dynamic Sequence Logo
To calculate the height of the amino acid symbol, Dynalogo first calculates the weight w  for each 
amino acid a at each position l . This can be calculated using the following formula with p  
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The observed probability is calculated from the selected samples and the background probability is 
calculated in one of three ways: naively (as even probabilities), based on the natural prevalence of the 
amino acids (from previous literature (Thomsen and Nielsen, 2012)) or from dataset background (from 
the current experiment). For the dataset background, the background frequencies are calculated using 
the data immediately prior to being thresholded (See Background Data in figure above). In a typical 
peptide binding array experiment where positively selected sequences are analyzed, the dataset 
background is a matrix of the frequencies of each residue at each position within the entire array. With 
the weight, the information content for that position  � (can be calculated by taking the sum of the 




This information content is then used to calculate the height for a specific amino acid at position l .
ha , l=I l∗pa , l∗sign ( w )
By including the sign of the weight in the equation, enriched amino acids will appear on the top of the 
logo while depleted ones will appear on the bottom. 
6.1.1.2 2. Importing Data
6.1.1.2.1 2-1 Acceptable Data Format
Dynalogo will accept data in tabular form as a tab, comma or semicolon delimited file. Data should be 
tabular with each row representing the interaction with one probe and one spot in a particular array. The
dataset should contain identifiers for the spot in the array, type of array (if multiple configurations are 
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used), and the experiment number or replicate information. It is also helpful if the dataset contains data 
on the location of the spot in the array with separate variables for the row and column information. In 
this way each spot can be uniquely identified and traced back to the original measurement. Below is an 
example of the types of data which can be included in the dataset. Some fields are required for the core 
functions, while others may be beneficial for some of the peripheral features. The actual naming of the 
columns is not crucial as the user will have the option to match the columns from their dataset to the 















LAB_pY58 100 20 FTGSRTYSLVGQA GRB2 A 25 Left L 5
6.1.1.2.2 2-2 Initial Data Preparation
Dynalogo software is capable of importing one or more delimited text files. As a basic rule these files 
should contain only the header values (column names) and the data values themselves. If there is any 
metadata associated with the file it should be removed and/or archived. 
Name (required)– Unique identifier for the sample spot in the array. This should identify one 
component in the protein–protein interaction experiment (e.g., peptide, ligand, etc.). Ideally a unique 
name for the peptide sequence should be used (e.g., Protien ID_site), but if one is not available, a 
unique numeric identifier (e.g., array spot ID) can be used. For proteomics data, simply use a unique 
identifier for a detected peptide fragment. The key is that this should be unique within an experiment or
replicate. Multiple sequences referenced with the same name (e.g., gene symbol, protein name etc.) 
may result in errors within the application. See Data Summation/Thresholding section 6-1 for more 
information. 
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Signal/Modified (required) – Binding intensity or signal value. If the data contains paired 
measurements (modified/unmodified, phosphorylated/unphosphorylated, etc.) this column should 
contain the foreground signal value best associated with the biological system (e.g., signal to 
phosphotyrosine peptide for SH2 domain binding assay). For binding experiments this quantity refers 
to a measurement of binding strength, but for other experiments (e.g., quantitative mass spectrometry) 
this could represent the quantitative measurement associated with each peptide sequence.
Background/Unmodified – This should be the second of the paired measurements which corresponds 
most with the background or resting state of the system. This column should be used if the desired 
metric is a ratio of the signal with another value. This ratio can then be used with the thresholding 
slider to explore the dataset.
Sequence (required) – Amino acid sequence corresponding to the spot in the peptide array or 
identified peptide fragment in mass spectrometry. These sequences should contain only letters and no 
intermediate symbols (e.g., DDKLLYT not DDKLLpYT). The characters should also be uppercase and 
limited to the set of 20 in the standard amino acid library and “X” if needed for padding. They must be
aligned and the same length. If it is desired to use sequences of differing lengths then they can be 
padded with the letter X to be brought to the same length. Protein modifications, e.g., pY, pT, pS, 
should be identified in a separate column, not within the sequences.  
Probe (required) – ID of probe used to bind to the peptides in the array (SH2, antibody, …). For other 
types of experiments this column should be used to identify the second protein in the protein-protein 
interaction. If no suitable option exists, the user can select a column which has identical values for all 
samples and ignore any further UI options for “Probe”.
Slide Template – Array type if more than one array layout was used. This allows for mapping different 
proteins/peptides to the same spots locations if different array layouts are used.
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Experiment ID - ID to differentiate replicated probing of array-probe combinations. Often the same 
probe array combination is repeated and this allows to determine experimental variations. For other 
types of experiments this can be used to identify different experimental runs. Experiment ID is required 
for the Boxplot.
Slide Position – ID to differentiate intra experiment replicates (i.e. multiple arrays on same slide 
“Right, Left”). This can be used to identify any type of replicate within the experiment.
Row of Spot - Row location of the spot in the array. This is necessary to fully utilize the digital binding 
visualization.
Column of Spot - Column location of the spot in the array. This is necessary to fully utilize the digital 
binding visualization.
Upon import, data is processed according to the following table. For processing, the names of the 
selected columns will be modified to match Dynalogo’s internal column names, as listed below. For all 
stages after data import the data in these columns will be referred to using the internal column name.










Column of Spot Column
6.1.1.2.3 2-3 Sample Dataset
For a dataset to experiment with, please download the zip file using the link in the application. The 
sample dataset contains three sets of results. These results were derived from binding experiments for 
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6,200 phosphotyrosine peptides with two SH2 domain probes, Grb2 and Vav2 (Tinti et al., 2013). The 
dataset contains three experiments, with one set of results from a Grb2 SH2 experiment (Experiment 
Number “SH2_GRB2”) and two sets of results from replicated two VAV2 SH2 experiments 
(Experiment Number “SH2_VAV2_1” and “SH2_VAV2_2”). All the peptides contain phosphotyrosine 
at the 7th position. The observed binding motif for the Grb2 SH2 domain is pYXN (pY is 
phosphotyrosine and X represents any amino acid) and for VAV2 it is pYLXP (Tinti et al., 2013). The 
data table contains 16 columns for which we will use six variables for the sample analysis: [spot_index]
for Name; [peptide_sequence] for Sequence; [Probe] for Probe; [experiment_ac] for Experiment 
Number; [Signal] for Signal; and [protein_short_name_temp] for Protein.
6.1.1.2.4 2-4 Importing Data Window
In this tutorial we will import and visualize the peptide array results with Vav2 and Grb2 SH2 domain 
probes from the dataset from the G. Cesareni Lab (Tinti et al., 2013).
1. First the user should open the data import dialogue by clicking on the “Import Dataset” button.
2. From the import data dialogue the three samples (Sample_SH2_Grb2_1.csv, 
Sample_SH2_VAV2_1.csv, Sample_SH2_VAV2_2.csv) can be imported. By clicking the browse 
button, the user can select the file and folder where the data is located. Multiple files can be selected for
import.
3. Once opened, the user will be able to see a preview of the data and the option to select the delimiter 
or separator for the file. If unsure of the type of delimiter the user can consult the preview window to 
see if the current setting is importing properly. “Tab” should be selected for the samples.
4.  Once properly selected, the user can then select the names of the columns containing the following 
data. This process will map the important columns in the data set to variables that the application will 
be able to recognize. For the sample set, select “spot_index for Name; “peptide_sequence” for 
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Sequence; “Signal” for Signal/Modified; and “domain_ac” for Probe; and “experiment_ac” for 
Experiment ID.  
5.  Proper selection should be confirmed by clicking the “OK” button, closing the dialogue. Once the 
data has been imported, it is recommended to export a reformatted version of original data. This allows 
users to export a single CSV file containing the imported data and reimport the same dataset without 
re-selecting the column contents. This can be achieved by using the export function at the bottom of the
application above the data table. The user should be sure to select “Imported Data” from the data table 
dropdown to the left of the download button. The new file will contain all the data as they were 
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originally imported, but with the last assigned column names. Of note, the exported file will be a CSV 
file and the “Comma” option for Separator should be selected. 
6.  Once complete, proper data import should result in the loading of the Visualization part of the 
application. If any errors are present it is possible that a mistake occurred during import and it may be 
wise to restart the application and try importing again. With large datasets it may take a few moments 
for these errors to disappear as the data is processed.
6.1.1.3 3. Visualization Display Selection Panel
Once the data is imported, the visualization display menu will appear at the top of the app, allowing the
user to control which figures to display simultaneously. Visualizing more displays at once can be 
helpful, but may also be less responsive (slower) due to the additional computation required.
6.1.1.4 4. Filtering & Transformation Panel
Dynalogo contains several options for data filtering and transformation. The data can be filtered by 
probe, slide template, or potentially another user selected column. The provided demo dataset does not 
contain multiple slide templates, however for a dataset with multiple array types, the "Select Template" 
option will appear below “Select Probes”. In addition the data can be calculated as a ratio between two 
columns (Signal/Background, Modified/Unmodified) and/or log transformed. Depending on the 
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distribution of the data it can be helpful to apply a log transformation before analysis. However, if the 
data contains negative values due to various experimental reasons including abnormally high 
background, the log transformation will not work properly. In this case it may make more sense to use a
ratio-metric approach where the foreground signal is divided by that of the background before applying
the log transformation. 
1) In the following examples, we will select an individual probe to be visualized. To avoid importing 
files multiple times, subsets of the imported data can be selected, either as individual or multiple 
probes.
2) For Graph, Logo, and Table panels, the user can combine multiple slide templates for analyses. The 
Distribution panel and Digital Binding may not work for multiple templates.
3) If additional filtering is required a custom dropdown is included which can allow for the selection of 
a column and a value within that column as a selection criterion. For instance, one could use this to 
explore a specific subset of their data (i.e. phosphorylated samples vs non phosphorylated samples). 
This would be accomplished by first selecting the name of the column describing the phosphorylation 
state of the sample from the “Select Column to Filter By” dropdown. Next they should select the 
desired state from drop down directly below. This will filter out any data not matching that state and 
will allow the analysis of the desired samples.
4) If the user wishes to analyze the data as ratio of two signals (Signal/Background, 
Modified/Unmodified) to explore modification-dependent binding such as SH2-pTyr, they can chose 
those columns from the dropdowns and toggle this feature with the checkbox. This feature does require
that the signal data for the two states be in two separate columns. If the modifications are structured as 
separate entries (separate spots in the array) then the data will need to be restructured so 
modified/unmodified are separate columns for the same entry.
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5) If desired, a log transformation can be applied to the data using the menu on the right. The sample 
data is already log transformed and thus this option should not be enabled for any of the sample 
analysis. Selecting this for the sample data may lead to errors within the application
6.1.1.5 5. Distribution Panel
After importing data it can be beneficial to visualize the overall distribution of the dataset. This can be 
accomplished using the distribution panel. Within the distribution panel the user can choose between a 
boxplot, histogram or scatterplot representation of the data. The users can analyze entire datasets or 
subset of imported data by selecting specific parameters such as “probe” or “protein” from the “Select 
Colum to Filter By” pane. For the following examples we will select VAV2 from the probe dropdown.
6.1.1.5.1 5-1 Boxplot 
If it is desired to visualize multiple replicates at once, the summary boxplot can be used. In this panel 
boxplots will be grouped based on the intra and inter experiment replicates. This can be useful for 
visually comparing differences in variation between inter or intra experiment replicates. To draw a 
boxplot, “Experiment ID” must be assigned when importing data. Two types of boxplot types are 
available. The “Summary” option allows for a quick overview of the result and downloading the image.
The “Interactive” option will display raw data for individual data points as well as basic statistics with 
a mouseover, but it is limited to showing the data at the Experimental level (No intra-experiment 
replicates will be shown). The Interactive option also has an option to download the image by clicking 
on the camera icon above the figure which will appear when the mouse is over the figure.
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6.1.1.5.2 5-2 Histogram
Another convenient way to display a data distribution is with the histogram viewer. With this the user 
can look at the overall shape of the data. If a view of a subset of the data is desired, the custom filter 
can be used to select the desired subset: use the “Select Column to Filter By” pane with the “Select 
Value” option.
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6.1.1.5.3 5-3 Scatter Plot
Individual replicates can be compared using the scatterplot option in the distribution display panel. 
Next one needs to select two specific datasets to compare. The simplest option is to select the column 
and specific instances using the interface to the left of the scatter plot. Using our VAV2 example, one 
can select the column “Experiment_Number” and below that select the experiment number for the x 
and y axes. The result should be something similar to the following:
Once the selection is complete, the result is displayed as an exportable 2-factor scattergram. In 
addition, the Pearson’s correlation coefficient is calculated between the two replicates. If more than two
types of replicates exist within the data set, the user can select an additional column using the custom 
filter. Thus they can isolate the type of replicate in question. 
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6.1.1.6  6. Data Summation/Thresholding Panel
The data summation/thresholding panel will always be displayed and is important for conducting any 
analysis using the Logo plot, Graph or Table. It allows the customization of three things; how to 
average over the replicates, which columns to keep and display, and how to threshold and remove 
samples from the dataset. 
6.1.1.6.1 6-1 Grouping/Averaging & Keeping Columns
The “Select Column to Group by” column selection requires that at least two items are selected. The 
default selection of “Name” and “Probe” assumes these columns can describe the unique binding pairs 
in the experiment. With the sample data we defined the “spot_index” (1,2,3...) as “Name” and the 
“domain_shortlabel” (Grb2, VAV2) as “Probe”. In that experiment these two items identify the 
components of the different binding pairs (probe and peptide ligand), essential components of the 
biological question. For other experiments which are not based on binding and do not have two specific
components, the “Probe” column can be any column where the value is constant for all samples.
The above selection will define how to group and average over the replicates by a specific category 
pair. The default setting will average the user-selected signal values (e.g., Signal/Modified) per “Name”
and “Probe”. An alternate approach would be selection of “Sequence” and “Probe” which will average 
the signal values per “Sequence” and “Probe”. With the sample data the former may make more sense 
when the user desires that all spots are kept separate, while the latter could be more desirable when the 
user is more interested in the averages of the spots for individual sequences. In general, additional 
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columns can be added to this selection when the user wants to avoid averaging the signal across 
different values in those columns. For example, if multiple slide templates are used (i.e. A, B, C etc.) 
then “slide_template” should be selected as well to prevent averaging across different slide layouts.
The “Select Columns to Keep” dropdown. allows the user to select columns of data that they would 
like retained for further analysis. As general rules, some columns (“Sequence,” “Signal”, “Name”, 
“Probe” and ”Z_Score”) are required for the visualization panels. If they are not included in the “Select
Column to Group by” selection, then they must be included in the second selection, the “Select 
Columns to Keep” dropdown. Usually “Name” and “Probe” will be selected in the first dropdown so 
“Sequence” and “Signal” should be included in the second. By default “Select Columns to Keep” 
selection also contains items necessary for calculations of common statistical parameters like average, 
standard deviation (SD), standard error of the mean (SEM), and z-score. Importantly, no item should be
selected by both “Group by” and “Columns to Keep”. 
6.1.1.6.2 6-2 Thresholding
The thresholding menu allows the user to dynamically adjust the cutoff for datapoints which will be 
used for visualization. With this menu the user can select how they want the data to be thresholded. By 
default, the Z_Score option is selected because it allows for some comparison between different probes 
or slide templates. z-score is the number of standard deviations a data point is away from the mean of a 
dataset. In this case the dataset consists of all of the spot-probe interactions for a single slide 
type/template. Thus, the z-score can give a measurement for the strength of the interaction in the 
context of all the interactions from that slide and is considered as a method of normalization. The 
second option is to threshold by the percentage of the maximum signal. This maximum is also 
calculated for a single slide-probe combination as explained for the Z score. With either option care 
should be taken when comparing multiple probes to consider the effects of various data characteristics 
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on either method. The percentage of maximum will be more influenced by lone high value outliers, 
while the z-score will be more influenced by shifts in the mean and should be limited to normally 
distributed data. Once the type of thresholding is selected, one is able to adjust this threshold and 
explore how the visualizations change. This can be particularly interesting when looking at the Logo 
plot output. In addition, there is the option to set the slider to automatically adjust so one can easily 
visualize the range of sequence preferences over different affinities (play/triangle button to start).
6.1.1.7 7. Logo Plot
A convenient way to visualize amino acid preferences of probe-peptide interactions is the sequence 
logo, a representation of the sequence conservation of amino acids as measured in bits (a measure of 
uncertainty or information). Where a consensus sequence shows only the most important residues at 
each position, a sequence logo displays a stack of symbols for each position in the sequence. Within 
each stack, the height of the symbols is proportional to the relative frequency of each base with the 
topmost symbol being the most common (Schneider and Stephens, 1990) . Several types of sequence 
logos have been developed to show residues which are either enriched or depleted and are indicated by 
their position above or below the axis. One example of this type of implementation, the Kullback-
Leibler logo can be found at http://www.cbs.dtu.dk/biotools/Seq2Logo/ (Thomsen and Nielsen, 
2012).This is the same type of sequence logo which is implemented in Dynalogo. As an example, 
another implementation of this visualization can be found at weblogo.threeplusone.com (Crooks et al., 
2004) . In Dynalogo this graphical representation updates dynamically using the threshold slider 
mentioned previously. Thus, allowing the user to scan through different threshold values and observe 
how the sequence logo changes. The controls to the left of the figure allow the user to select the desired
background type, and to export the figure. The first option “Even Distribution” assumes all residues 
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occur with equal frequency. The default and second setting “Natural Occurrence” is based on the 
frequencies of amino acids in eukaryota as below (Chen et al., 2013).
Amino acid A R N D C Q E G H I
Frequency 7.92% 5.79% 4.18% 5.39% 1.82% 4.15% 6.40% 6.51% 2.44% 5.02%
Amino acid L K M F P S T W Y V
Frequency 9.18% 5.52% 2.19% 3.75% 5.47% 8.33% 5.81% 1.22% 2.82% 6.15%
The third option “Experimental” is calculated from the sequence column of the imported data capturing
any bias in overall array composition. For example, the sample data contains sequences which by 
design always contain a tyrosine at the seventh position. Using the “Experimental” option, this artificial
enrichment is deemphasized. The figure below can be created by selecting GRB2 from the probe 
dropdown; Name and Probe from the Group By dropdown and adjusting the threshold slider to a z-
score of 2. As mentioned above, the log can be dynamically displayed with auto-thresholding. 
1. Select “Logo plot” in the top panel.
2. Select a pair of column tags which represent your binding pair, e.g., “Name” (peptide ID) and 
“Probe” (see above for more detail). 
3. Select column tags available for further analysis. In most of cases, “Signal” and “Sequence” are 
appropriate.
4. Select threshold method, either “Z_Score” or “Average_Signal”.
5. Select type of thresholding.
6. Select the type of background (see above for more detail).
7. Set threshold using the scale bar directly or by starting and stopping autorun using the triangle.
8. To download a logo image, set a filename, file type (svg, png, pdf, or eps), and image dimensions 
and press “Export”. 
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6.1.1.8 8. Graph 
The graph panel allows the user to compare average signal or z-score values between samples. If more 
than one probe is selected, the visualization will result in a stacked barplot with the colors indicating 
the different probes. This feature is useful to identify unique and common binders. Within the graph 
panel are the options to select the data for x and y axis in the drop-downs on the right. Also, there is the
option to sort the x axis ascending/descending to create a waterfall type chart. If the x axis labels are 
too big they can be resized with the slider or hidden with the checkbox. Also, it is possible to get 
information about individual bars when hovering the mouse if the Interactive checkbox is selected. All 
non interactive plots can be exported as a png or svg using the menu. For this particular dataset, the 
unique identifiers used are spot numbers. 
If the user is interested in a specific bar they may want to have the plot display the short protein name 
associated with the spot numbers. To do this they need to make sure that column is selected in the 
“Data Summation/Thresholding” panel. In this case the column “protein” needs to be added, as shown 
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below. Once present in this panel. The column “protein” can then be selected as the x-axis data. X-axis 
names which are too long may cause the graph to load improperly. To fix this the x axis labels can be 
hidden and the graph made interactive to replace the lost labels with mouse over labels. 
6.1.1.9 9. Digital Binding
The digital binding panel allows the user to view data with the orientation of the original array. This 
can be helpful for identifying sources of strong signals and comparing with the original images. To take
full advantage of this feature, the dataset should contain two columns (“Row”, “Column”) representing 
the spots location in the array. If these columns are not present the data can still be visualized, but not 
in a way that corresponds to the original image. If more than 384 spots exist than they will split up over
multiple groups of 384 which can be selected using the slider in the middle. With the default setting 
this visualization shows the averages over the various replicates or experiments for the “Probe” 
selected. If the user desires to visualize only one replicate or experiment, maybe to look for anomalies 
in the array, they can select the replicates using the “Select Column to Filter By” tool near the top of 
the application. To do this the user must first select the column with the replicates or experiments from 
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“Select Column to Filter By” and then select the actual replicate or experiment Id from the “Select 
Value” drop-down. An example of this with the sample data would be to select “Experiment_Number” 
for the column and one of the Experiment IDs in the second drop-down. By switching between 
experiments, the user can easily look for anomalies associated with a specific experiment. 
It can also be useful to compare individual spots or sites between probes.   Using the slider at the top 
left of the panel, the user can switch between various probes to look for sites which may change the 
most or the least. Depending on the dataset it may be desired to customize the popup label for the spots.
Using the dropdown on the right side of the panel, the user can select how they would like the spots to 
be labeled. This can be particularly useful with the example data set where the names of the proteins 
are in another column. Again, the user will have to make sure the desired column is first selected in the 
Data Summation/Thresholding panel under “Select Columns to Keep”. Once selected there the desired 
column should appear in the “Select Label for Spots” dropdown in the Digital Binding panel.
6.1.1.10 10. Interactive Table and Data Export
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The table panel is always present and updating with the rest of the application. It allows for the export 
of any dataset used in the application and these datasets can be selected from the control panel above 
the table. Within these datasets the user can also search for keywords to further refine the dataset. This 
can be particularly useful when looking at sequence motifs associated with a specific logo. One can 
search for a particular sequence using wildcards. For example, searching for “......Y.V....” will look for 
any sequence which has 13 amino acids with a tyrosine, followed by a Valine two positions later. The 
“.” represents an individual amino acid which is not specified, often represented as an “x” in the 
literature. The table can be searched globally or by individual column.  For the simplicity of the app, 
modifications of amino acids such as phosphotyrosine and phosphoserine are not represented in the 
sequence and thus cannot be searched by text. The options in the Select Data dropdown correspond to 
the datasets used in various panels of the application. This allows the use to view and export the 
manipulated data used for each figure (for a visualization of the processing work flow of this data, see 




The table below includes several common issues and the potential causes and solutions for the problem.
In the description of the problem, the bolded title indicates the location where the user would encounter
the issue.
Category and Problem Potential Causes Potential Solutions
Import:
Import screen will not disappear
Mandatory drop-down not 
selected
Ensure all red drop-downs are selected
Import:
Data does not contain a column 
which fits Probe description
Experiments which do not 
concern pairwise interactions
but still are interested in 
analyzing a subset of 
sequence data
Workaround: User can select any column 
where the values are the same for all 
samples. They should then ignore all 
interface options for manipulating the 
“Probe”.
Summation/Thresholding:
Scale bar for z-score is missing
Missing value for “Signal”
Review dataset and correct or remove data 
point
Barplot Display:
Ascending or descending barplot 
contain data points that appear out 
of order
Unique column tag selected 
in “group by” is not unique 
(e.g., “Name”, “Sequence”) 
and multiple entries are 
being stacked in the same 
position
Try using other unique tag (“Name”, 
“Sequence”) or consider processing data 
differently
Visualizations:
Graph or Logo plot won’t display  
Redundant column tag in 
Data Summation drop-
downs
Remove duplicate tag (See Section 6-1)




Log2 transform causes errors
Data contains negative 
values which result in 
imaginary numbers when log
transformed
Avoid log transform or reprocess data to 
ensure no negative numbers are present
Visualizations:
Scatterplot results in an error
Selection for “Name” 
contains redundant values
Select column for “Name” with unique 
values (e.g., spot_index)
Experiment ID not selected 
in import
Select Experiment ID during import
Visualizations:
Error: No Samples Left in Dataset
Nothing Selected in “Select 
Templates”
Make selection in “Select Templates”




Specific Column does not appear in
table
Column name may have 
changed in import




Specific column name does not 
appear in drop-down
Column is not included in 
“columns to keep” drop-
down
Add column to “columns to keep” drop-
down
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